{"text": "After four weeks in the study , none of the patients treated with gefitinib and docetaxel remained in the WHO grade 0 category , and at the end of the treatment cycle , four patients had a WHO grade 2 performance status .", "label": "", "metadata": {}, "score": "26.360905"}
{"text": "Five patients treated with gefitinib and docetaxel and three patients treated with placebo and docetaxel were reported with serious adverse events ( SAEs - see Table 3 ) .", "label": "", "metadata": {}, "score": "29.182093"}
{"text": "Correspondingly , six and five patients , receiving gefitinib or placebo in combination with docetaxel , respectively , were taken off the study medication due to objective progression of the disease .", "label": "", "metadata": {}, "score": "29.666847"}
{"text": "Based on extrapolation from a pharmacokinetic study with ketoconazole in 7 patients , consider a 50 % docetaxel dose reduction if patients require co - administration of a strong CYP3A4 inhibitor .", "label": "", "metadata": {}, "score": "33.657524"}
{"text": "Importantly , among 112 patients who had completed first - line carboplatin - paclitaxel , 106 ( 94.6 % ) received second - line gefitinib and 58.5 % of these patients had a response .", "label": "", "metadata": {}, "score": "33.728676"}
{"text": "One patient in the placebo - treated group had a CTC grade 4 neutropenia during the treatment .Six gefitinib - treated , but only two placebo - treated , patients experienced a grade 3 fatigue .", "label": "", "metadata": {}, "score": "34.2071"}
{"text": "In Study 1 , patients received a median of 4 doses ( range 1 - 34 ) of Cyramza or a median of 3 doses ( range 1 - 30 ) of placebo .", "label": "", "metadata": {}, "score": "34.39518"}
{"text": "An open - label randomized phase 2 study ( SIGN trial - Second line Indication of Gefitinib in NSCLC ) compared gefitinib ( 250 mg / day ) with docetaxel ( 75 mg / mq every 3 weeks ) in 135 patients with advanced pretreated NSCLC [ 32 ] .", "label": "", "metadata": {}, "score": "34.792503"}
{"text": "In addition , doxorubicin and cyclophosphamide had no effect on docetaxel plasma clearance when the three drugs were given in combination compared to historical data for docetaxel monotherapy .", "label": "", "metadata": {}, "score": "34.948196"}
{"text": "Only one patient experienced neutropenia as a serious adverse event .This is in contrast to the two published studies on the combined treatment with gefitinib and docetaxel given every third week [ 11 , 12 ] .", "label": "", "metadata": {}, "score": "35.55697"}
{"text": "The incidences of rash or acne , diarrhea , and elevated aminotransferase levels were significantly higher with gefitinib , whereas neurotoxic effects , nausea and vomiting , and hematologic toxic effects were significantly higher with carboplatin - paclitaxel .", "label": "", "metadata": {}, "score": "36.383617"}
{"text": "A meta - analysis of the randomized clinical trials comparing gefitinib to docetaxel was presented at 2009 ASCO Meeting and showed similar overall and progression - free survival between the two drugs and superior response rate with gefitinib [ 37 ] .", "label": "", "metadata": {}, "score": "36.552208"}
{"text": "Adverse reactions resulting in discontinuation of any component of the Cyramza plus paclitaxel combination in 2 % or more patients in Study 2 were neutropenia ( 4 % ) and thrombocytopenia ( 3 % ) .", "label": "", "metadata": {}, "score": "37.380882"}
{"text": "Two groups of patients were analyzed : those who had received prior chemotherapy and those who had not .This analysis suggested two recommended doses : 75 mg / m\u00b2 of docetaxel combined with 700 mg / m\u00b2 of cyclophosphamide in previously treated patients , and 75 mg / m\u00b2 of docetaxel combined with 800 mg / m\u00b2 of cyclophosphamide in previously untreated patients .", "label": "", "metadata": {}, "score": "37.581978"}
{"text": "Explanations of the negative results of this trial could be the large number of chemotherapy refractory patients ( 90 % ) , a suboptimal dose of gefitinib and the lack of selection based on potential molecular markers , associated with clinical outcome . , while patients with EGFR mutations obtained higher RR than wild - type patients ( 37.5 % versus 2.6 % ) [ 31 ] .", "label": "", "metadata": {}, "score": "37.585777"}
{"text": "However , gefitinib had a more favorable tolerability profile than docetaxel ( adverse events of all grades : 51.5 % versus 78.9 % ; grade 3 - 4 : 8.8 % versus 25.4 % ) .", "label": "", "metadata": {}, "score": "37.97975"}
{"text": "Although the studied treatment regimen was safe , the response rate was lower than predicted and the study was terminated .Docetaxel is a well - established agent in the treatment of SCCHN [ 6 - 8 , 24 ] , and probably there was more added efficacy by combing it with gemcitabine .", "label": "", "metadata": {}, "score": "38.255936"}
{"text": "Patients experiencing treatment delays were retreated after recovery with docetaxel 30 mg / m 2 , except for patients with neutropenia lasting less than 7 days .", "label": "", "metadata": {}, "score": "38.478706"}
{"text": "The study met the primary objective ( non inferiority of gefitinib ) and also demonstrated the superiority of gefitinib compared to carboplatin and paclitaxel in terms of progression - free survival in intention - to - treat analysis ( HR 0.74 , 95 % CI : 0.65 - 0.85 , . )", "label": "", "metadata": {}, "score": "38.598972"}
{"text": "Discussion .The aim of this study was to investigate the feasibility and activity of combining the oral tyrosine kinase inhibitor gefitinib with docetaxel .The tolerability of chemotherapy has generally been improved by the introduction of weekly based dosing regimens , as demonstrated for both paclitaxel and docetaxel with no reduction in efficacy ( for review see [ 29 ] ) .", "label": "", "metadata": {}, "score": "38.75471"}
{"text": "The performance status at study inclusion did not differ , as shown in Table 1 .Study Treatment and Study Discontinuation .The patients randomized to the combined treatment group received a median of 40 doses of gefitinib tablets ( range 16 - 130 ) , whereas the median number of received doses for the control patients was 84 doses of placebo tablets ( range 11 - 161 ) .", "label": "", "metadata": {}, "score": "38.826523"}
{"text": "The most frequent adverse events were an acne - like rash and gastrointestinal side effects .Two of 6 patients at 700 mg / day had DLT ; no further dose escalation occurred .", "label": "", "metadata": {}, "score": "38.879654"}
{"text": "Docetaxel doses ranged from 60 to 85 mg / m\u00b2 and cyclophosphamide doses ranged from 600 to 800 mg / m\u00b2 .All patients received steroid prophylaxis .", "label": "", "metadata": {}, "score": "38.982216"}
{"text": "However , treatment with gefitinib was not associated with significant improvement in survival in the overall population ( 5.6 versus 5.1 months in the gefitinib and placebo arms , resp . ) nor in the subgroup of patients with adenocarcinoma .", "label": "", "metadata": {}, "score": "39.063087"}
{"text": "Although all the comparisons have weak power due to the small number of the patients , these results are very striking and preclude the use of adjuvant gefitinib outside from clinical trials .", "label": "", "metadata": {}, "score": "39.20708"}
{"text": "Although there was no excess in grade 4 or 5 toxicity in the BV arms , grade 3 adverse events were higher in the BV arms compared to the placebo arm .", "label": "", "metadata": {}, "score": "39.2844"}
{"text": "Patient Demography and Previous Treatment .A total of 18 patients were included in this study .Nine patients were randomized to receive gefitinib 250 mg QD and nine to receive a matched placebo preparation .", "label": "", "metadata": {}, "score": "39.451057"}
{"text": "The interim analysis of this study showed that the hypothesized alternative of a 33 % improvement in survival with gefitinib over placebo was ruled out with a one - sided .", "label": "", "metadata": {}, "score": "39.71447"}
{"text": "A second randomized phase 3 clinical trial compared gefitinib ( 250 mg daily ) with cisplatin - gemcitabine as a first - line treatment in 309 Asian , never smokers patients , with advanced adenocarcinoma [ 58 ] .", "label": "", "metadata": {}, "score": "39.74743"}
{"text": "Red blood cell transfusions were given to 11 % of Cyramza - treated patients versus 8.7 % of patients who received placebo .Table 2 provides the frequency and severity of adverse reactions in Study 1 .", "label": "", "metadata": {}, "score": "39.817787"}
{"text": "Overall survival and progression - free survival were statistically significantly improved in patients randomized to receive Cyramza plus docetaxel compared to patients randomized to receive placebo plus docetaxel .", "label": "", "metadata": {}, "score": "39.820126"}
{"text": "The most common grade 3 - 4 nonhematologic adverse event was hyponatremia , which occurred in 10 ( 30 % ) patients ( Table 3 ) .", "label": "", "metadata": {}, "score": "39.89953"}
{"text": "However , the patients randomized to receive gefitinib were given 46 , 21 , and 5 infusions in the first , second , and third treatment cycle , respectively .", "label": "", "metadata": {}, "score": "39.92174"}
{"text": "The inclusion of 66 patients was planned .The study was closed due to treatment - related toxicity .Of the 18 included patients , seven ( of which three received gefitinib ) were withdrawn from the study due to toxicity .", "label": "", "metadata": {}, "score": "40.089317"}
{"text": "Treatment discontinuation due to adverse reactions occurred more frequently in Cyramza plus docetaxel - treated patients ( 9 % ) than in placebo plus docetaxel - treated patients ( 5 % ) .", "label": "", "metadata": {}, "score": "40.115036"}
{"text": "The patients received 8 mg dexamethasone prior to the first and second infusion of docetaxel , and the dose was thereafter reduced to 4 mg dexamethasone .", "label": "", "metadata": {}, "score": "40.35804"}
{"text": "Based on these phase II studies , single - agent docetaxel 75 - 100 mg / m 2 IV every 3 weeks was shown to be an active and generally well - tolerated regimen for metastatic or recurrent SCCHN .", "label": "", "metadata": {}, "score": "40.383766"}
{"text": "J Clin Oncol 13:2643 - 2655 , 1995 .Di\u00e9ras V , Chevallier B , Kerbrat P , et al : A multicentre phase II study of docetaxel 75 mg / m2 as first - line chemotherapy for patients with advanced breast cancer : Report of the Clinical Screening Group of the EORTC .", "label": "", "metadata": {}, "score": "40.46115"}
{"text": "Rash , diarrhea , and nausea were the most common adverse events .The positive results obtained in early phase 2 clinical trials with gefitinib were not confirmed in large phase 3 trials in unselected patients with advanced NSCLC .", "label": "", "metadata": {}, "score": "40.587868"}
{"text": "Both trials excluded patients with Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) of 2 or greater , uncontrolled hypertension , major surgery within 28 days , or patients receiving chronic anti - platelet therapy other than once daily aspirin .", "label": "", "metadata": {}, "score": "40.667828"}
{"text": "Among the 33 treated patients : 13 ( 39 % ) patients had grade 3 - 4 anemia , 10 ( 30 % ) had grade 3 - 4 neutropenia .", "label": "", "metadata": {}, "score": "40.889557"}
{"text": "Deaths within 30 days of last study treatment occurred in 31 patients ( 7.6 % ) in the docetaxel+cisplatin arm and 37 patients ( 9.3 % ) in the vinorelbine+cisplatin arm .", "label": "", "metadata": {}, "score": "41.41122"}
{"text": "Phase III Clinical Studies in Second - Line Therapy .A multicenter phase 3 study compared gefitinib as monotherapy at the dose of 250 mg / day to placebo in 1692 pretreated patients with NSCLC [ 30 ] .", "label": "", "metadata": {}, "score": "41.411667"}
{"text": "Three patients in the gefitinib - treated group were taken off the study due to treatment - related toxicity , and the treatment for two of these patients was terminated in the first treatment cycle .", "label": "", "metadata": {}, "score": "41.546597"}
{"text": "In three cancer patients , the in vitro binding to plasma proteins was found to be approximately 97 % .Dexamethasone does not affect the protein binding of docetaxel .", "label": "", "metadata": {}, "score": "41.87475"}
{"text": "Grade 1 - 4 neutropenia occurred in 15 % of XTANDI patients ( 1 % Grade 3 - 4 ) and in 6 % on placebo ( no Grade 3 - 4 ) .", "label": "", "metadata": {}, "score": "42.06527"}
{"text": "PURPOSE : Randomized phase II trial to compare the effectiveness of two regimens of docetaxel in treating patients who have not previously received chemotherapy for unresectable stage IIIB or stage IV non - small cell lung cancer .", "label": "", "metadata": {}, "score": "42.152107"}
{"text": "Data from Western and Asian patients suggest that there was no statistically significant difference in overall survival between patients receiving EGFR inhibitors as a first - line therapy or after failure of previous chemotherapy [ 68 , 69 ] .", "label": "", "metadata": {}, "score": "42.326412"}
{"text": "The most common serious adverse events with Cyramza plus docetaxel were febrile neutropenia ( 14 % ) , pneumonia ( 6 % ) , and neutropenia ( 5 % ) .", "label": "", "metadata": {}, "score": "42.529747"}
{"text": "457 - 462 , 1999 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . Y. Inuyama , A. Kataura , K. Togawa et al . , \" Late phase II clinical study of RP56976 ( docetaxel ) in patients with advanced / recurrent head and neck cancer , \" Gan To Kagaku Ryoho , vol .", "label": "", "metadata": {}, "score": "42.74907"}
{"text": "Single - agent docetaxel was previously evaluated in four phase II studies involving approximately 160 patients with metastatic or recurrent SCCHN .The overall response rates observed in these studies ranged from 21 % to 42 % [ 2 - 5 ] .", "label": "", "metadata": {}, "score": "42.75656"}
{"text": "In phase I / II trials evaluating the combination of docetaxel and cisplatin the overall response rates were 33 % to 40 % [ 6 - 8 ] .", "label": "", "metadata": {}, "score": "42.859745"}
{"text": "The patients were randomized to receive gefitinib 250 mg or a matched placebo tablet once daily during participation in the study .In each seven - week treatment cycle , the patients were given docetaxel every week for six weeks , followed by a one - week treatment rest .", "label": "", "metadata": {}, "score": "43.096912"}
{"text": "Because clinical trials are conducted under widely varying conditions , adverse reaction rates observed in the clinical trials of a drug can not be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice .", "label": "", "metadata": {}, "score": "43.20346"}
{"text": "Due to the small number of patients treated , it is not possible to evaluate the efficacy and activity of the gefitinib / docetaxel combination .", "label": "", "metadata": {}, "score": "43.21482"}
{"text": "Four of 570 patients ( 0.7 % ) who received Cyramza as a single agent in clinical trials experienced gastrointestinal perforation .In Study 2 , the incidence of gastrointestinal perforation was also increased in patients that received Cyramza plus paclitaxel ( 1.2 % ) as compared to patients receiving placebo plus paclitaxel ( 0.3 % ) .", "label": "", "metadata": {}, "score": "43.2397"}
{"text": "Among 26 patients whose best response to an anthracycline had been progression , the response rate was 34.6 % ( 95 % C.I. : 17.2 - 55.7 ) , similar to the response rate in single arm studies of 100 mg / m 2 .", "label": "", "metadata": {}, "score": "43.251575"}
{"text": "Cyclophosphamide and Doxorubicin :A study was conducted in 30 patients with advanced breast cancer to determine the potential for drug - drug - interactions between docetaxel ( 75 mg / m 2 ) , doxorubicin ( 50 mg / m 2 ) , and cyclophosphamide ( 500 mg / m 2 ) when administered in combination .", "label": "", "metadata": {}, "score": "43.415176"}
{"text": "Clinical Response and Time to Tumor Progression .One patient treated with gefitinib and four patients in the placebo - treated group experienced a partial response on the therapy given .", "label": "", "metadata": {}, "score": "43.58143"}
{"text": "Treatment discontinuation of any study drug due to adverse reactions occurred more frequently in Cyramza plus FOLFIRI - treated patients ( 29 % ) than in placebo plus FOLFIRI - treated patients ( 13 % ) .", "label": "", "metadata": {}, "score": "43.603783"}
{"text": "No clinically meaningful changes in the exposure of either ramucirumab or its concomitant drugs in the approved combinations , including paclitaxel , docetaxel , and irinotecan ( or its active metabolite , SN-38 ) , were observed in patients with solid tumors .", "label": "", "metadata": {}, "score": "43.62063"}
{"text": "Patients with skin rash were allowed dose interruptions in the study medication ( gefitinib or placebo ) for up to 14 days , and supportive therapy such as antibiotics , steroid creams , and antihistamines were administered .", "label": "", "metadata": {}, "score": "43.744495"}
{"text": "Patients were also required to have ECOG PS 0 or 1 .Patients were randomized to receive either Cyramza at 10 mg / kg or placebo by intravenous infusion , in combination with docetaxel at 75 mg / m 2 every 21 days .", "label": "", "metadata": {}, "score": "43.7537"}
{"text": "Thirteen ( 39 % ) of the 33 treated patients had grade 3 - 4 anemia , and 10 ( 30 % ) patients had grade 3 - 4 neutropenia .", "label": "", "metadata": {}, "score": "43.975975"}
{"text": "Negative results were similarly observed with the combination of another tyrosine kinase inhibitor , erlotinib , with chemotherapy ( TALENT and TRIBUTE studies ) [ 26 , 27 ] .", "label": "", "metadata": {}, "score": "43.99102"}
{"text": "Patients in the gefitinib group had a clinically relevant improvement in quality of life , as assessed by FACT - L questionnaire ( OR 1.34 ; 95 % CI 1.06 - 1.69 , . )", "label": "", "metadata": {}, "score": "44.022827"}
{"text": "Secondary endpoints are overall survival , progression - free survival , safety , psycho - neurological effects , and quality of life .A phase IV pharmacoeconomics study will have the objective to analyze the cost - effectiveness and the cost - utility of gefitinib as a first - line treatment for 200 patients affected by stage IIIB or IV NSCLC , compared with the conventional first - line platinum - based chemotherapy ( ClinicalTrials.gov ID : NCT00173524 ) .", "label": "", "metadata": {}, "score": "44.08759"}
{"text": "9652 , pp .1809 - 1818 , 2008 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .J. Y. Douillard , F. A. Shepherd , V. Hirsh et al . , \" Molecular predictors of outcome with gefitinib and docetaxel in previously treated non - small - cell lung cancer : data from the randomized phase III INTEREST trial , \" Journal of Clinical Oncology , vol .", "label": "", "metadata": {}, "score": "44.184013"}
{"text": "More than 60 % of patients in each arm had liver metastases , and more than 40 % had lung metastases .Patients were randomized to receive docetaxel ( 75 mg / m 2 ) on day 1 and either gemcitabine ( 1,000 mg / m 2 ) on days 1 and 8 or capecitabine ( 1,250 mg / m 2 twice daily ) on days 1 to 14 .", "label": "", "metadata": {}, "score": "44.202896"}
{"text": "Therefore , this study has demonstrated that genotype - directed EGFR - TKI therapy with gefitinib for patients with previously untreated NSCLC is feasible also in a Western population .", "label": "", "metadata": {}, "score": "44.25406"}
{"text": "Grade 3 dehydration and electrolyte disturbances were seen in four patients treated with gefitinib , but not in patients treated with placebo .One patient treated with gefitinib was found to have a deep vein thrombosis , and one placebo - treated patient had a subclavian vein thrombosis , both CTC grade 3 events .", "label": "", "metadata": {}, "score": "44.29755"}
{"text": "Moreover , treatment with gefitinib was associated with evidence of high objective response rate , better quality of life and more favourable toxicity profile .Similar results have been recently obtained with erlotinib in a phase 3 clinical trial conducted in China ( the OPTIMAL trial ) , comparing erlotinib to gemcitabine plus carboplatin , in EGFR - mutation - positive tumors in terms of progression - free survival [ 66 ] .", "label": "", "metadata": {}, "score": "44.31346"}
{"text": "Although efficacy was similar , however , the toxicity profiles were different .Patients receiving gemcitabine/ docetaxel had significantly fewer nonhematologic toxicities , including hand - foot syndrome , mucositis , and diarrhea .", "label": "", "metadata": {}, "score": "44.32671"}
{"text": "4 , pp .413 - 423 , 2010 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus Two Regimens of Docetaxel in Treating Patients Who Have Not Received Chemotherapy For Unresectable Stage IIIB or Stage IV Non - Small Cell Lung Cancer .", "label": "", "metadata": {}, "score": "44.329353"}
{"text": "7 , no .5 , pp .1459 - 1465 , 2001 .View at Google Scholar \u00b7 View at Scopus . F. Ciardiello , T. Troiani , F. Caputo et al . , \" Phase II study of gefitinib in combination with docetaxel as first - line therapy in metastatic breast cancer , \" British Journal of Cancer , vol .", "label": "", "metadata": {}, "score": "44.335228"}
{"text": "Efficacy results are shown in Table 7 and Figure 2 .Non - Small Cell Lung Cancer .Study 3 was a multinational , randomized , double - blind , study of Cyramza plus docetaxel versus placebo plus docetaxel , that randomized ( 1:1 ) 1253 patients with NSCLC with disease progression on or after one platinum - based therapy for locally advanced or metastatic disease .", "label": "", "metadata": {}, "score": "44.34234"}
{"text": "Hypothesis , Statistical Analysis , and Patient Number Calculations .To warrant further evaluation , the response rate for the gefitinib plus docetaxel treatment arm must be at least 5 % greater than the placebo arm .", "label": "", "metadata": {}, "score": "44.373432"}
{"text": "5 , pp .777 - 784 , 2004 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .R. S. Herbst , G. Giaccone , J. H. Schiller et al . , \" Gefitinib in combination with paclitaxel and carboplatin in advanced non - small - cell lung cancer : a phase III trial - INTACT 2 , \" Journal of Clinical Oncology , vol .", "label": "", "metadata": {}, "score": "44.71257"}
{"text": "5 , pp .777 - 784 , 2004 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .R. S. Herbst , G. Giaccone , J. H. Schiller et al . , \" Gefitinib in combination with paclitaxel and carboplatin in advanced non - small - cell lung cancer : a phase III trial - INTACT 2 , \" Journal of Clinical Oncology , vol .", "label": "", "metadata": {}, "score": "44.71257"}
{"text": "Three of 9 patients treated at 700 mg / day developed DLT ( reversible grade 3 diarrhea ) .Four of 16 patients with NSCLC had partial responses ( observed from 300 to 700 mg / day ) .", "label": "", "metadata": {}, "score": "44.766865"}
{"text": "Docetaxel did not reduce fertility in rats when administered in multiple intravenous doses of up to 0.3 mg / kg ( about 1/50 th the recommended human dose on a mg / m 2 basis ) , but decreased testicular weights were reported .", "label": "", "metadata": {}, "score": "44.92865"}
{"text": "OBJECTIVES : .Primary .Compare the effects of two different schedules of docetaxel on the incidence of grade 3 and 4 toxic effects in older or poor performance chemotherapy - na\u00efve patients with unresectable stage IIIB or IV non - small cell lung cancer .", "label": "", "metadata": {}, "score": "45.01474"}
{"text": "401 - 409 , 2006 .View at Google Scholar . E. S. Kim , V. Hirsh , T. Mok et al . , \" Gefitinib versus docetaxel in previously treated non - small - cell lung cancer ( INTEREST ) : a randomised phase III trial , \" The Lancet , vol .", "label": "", "metadata": {}, "score": "45.09171"}
{"text": "The authors concluded that the addition of BV to docetaxel improved PFS , but the absolute improvement was only 0.7 - 0.8 months ( 8.0 vs. 8.7/8.8 months ) .", "label": "", "metadata": {}, "score": "45.110893"}
{"text": "This was also the case for the patient with subclavian vein thrombosis , who received placebo and docetaxel .SNP Analysis .Due to the relatively large proportion of patients with adverse events in both the gefitinib- and placebo - treated groups , we wanted to investigate if the toxicity seen could be related to genotypic determinants of docetaxel metabolism .", "label": "", "metadata": {}, "score": "45.209732"}
{"text": "Carcinogenesis , Mutagenesis , Impairment of Fertility .Carcinogenicity studies with docetaxel have not been performed .Docetaxel was clastogenic in the in vitro chromosome aberration test in CHO - K 1 cells and in the in vivo micronucleus test in mice administered doses of 0.39 to 1.56 mg / kg ( about 1/60 th to 1/15 th the recommended human dose on a mg / m 2 basis ) .", "label": "", "metadata": {}, "score": "45.29673"}
{"text": "Treatment with gefitinib seemed to be less well tolerated when given in combination with docetaxel dosed weekly ( our study ) compared to the every third - week dosing regimens [ 11 , 12 ] .", "label": "", "metadata": {}, "score": "45.32955"}
{"text": "For patients with no prior chemotherapy , the MTDs were 75 mg / m\u00b2 of docetaxel and 800 mg / m\u00b2 of cyclophosphamide .The dose - limiting toxicity was neutropenic fever , observed in 41 % of patients and 13 % of cycles .", "label": "", "metadata": {}, "score": "45.45466"}
{"text": "Two - thirds of patients had received adjuvant chemotherapy prior to this trial : 50 % antracyclines and 15 % taxanes .PFS was statistically significantly improved for both BV dose groups compared to the placebo groups .", "label": "", "metadata": {}, "score": "45.52945"}
{"text": "4 , pp .1307 - 1314 , 2010 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . F. A. Shepherd , J. Douillard , M. Fukuoka , et al . , \" Comparison of gefitinib and docetaxel in patients with pretreated advanced non - small cell lung cancer ( NSCLC ) : meta - analysis from four clinical trials , \" Journal of Clinical Oncology , vol .", "label": "", "metadata": {}, "score": "45.61738"}
{"text": "Patients continued to receive treatments in the absence of any grade 2 or higher toxicities .Patients who failed to achieve hematologic recovery for 3 consecutive weeks or more than 4 weeks for nonhematologic toxicities were removed from the study .", "label": "", "metadata": {}, "score": "45.743523"}
{"text": "Approximately one - half of patients had received prior chemotherapy for metastatic disease , and one - half entered the study following relapse after adjuvant therapy .", "label": "", "metadata": {}, "score": "45.74952"}
{"text": "Only one patient in the study , randomized to the placebo arm , was started on cycle four , but did not finish this treatment cycle .", "label": "", "metadata": {}, "score": "45.98797"}
{"text": "In the Korean study , gefitinib improved significantly objective response rate ( 28.1 versus 7.6 % ) and PFS ( HR 0.73 , 90 % CI 0.53 - 0.98 , . ) than docetaxel [ 36 ] .", "label": "", "metadata": {}, "score": "46.064964"}
{"text": "Preliminary data suggest that enzalutamide does not affect tolerability of docetaxel or have a clinically meaningful impact on docetaxel pharmacokinetics in this patient population .Overall , enzalutamide was well tolerated with no patients discontinuing because of an enzalutamide - related adverse event .", "label": "", "metadata": {}, "score": "46.091404"}
{"text": "K. Kelly , K. Chansky , L. E. Gaspar et al . , \" Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non - small - cell lung cancer : SWOG S0023 , \" Journal of Clinical Oncology , vol .", "label": "", "metadata": {}, "score": "46.129353"}
{"text": "Forty percent of the patients in this study had a history of prior paclitaxel exposure .The primary endpoint was survival in both trials .The efficacy data for the Taxotere 75 mg / m 2 arm and the comparator arms are summarized in Table 15 and Figures 3 and 4 showing the survival curves for the two studies .", "label": "", "metadata": {}, "score": "46.229324"}
{"text": "Contraindications .Warnings and Precautions .Cyramza increased the risk of hemorrhage and gastrointestinal hemorrhage , including severe and sometimes fatal hemorrhagic events .In Study 1 , the incidence of severe bleeding was 3.4 % for Cyramza and 2.6 % for placebo .", "label": "", "metadata": {}, "score": "46.22963"}
{"text": "270 - 356 , 2001 .View at Google Scholar \u00b7 View at Scopus .K. Syrigos , E. Karapanagiotou , A. Charpidou et al . , \" Biweekly administration of docetaxel and gemcitabine for elderly patients with advanced non - small cell lung cancer : a phase II study , \" Journal of Chemotherapy , vol .", "label": "", "metadata": {}, "score": "46.294167"}
{"text": "Increased TSH levels were observed in 53 ( 46 % ) patients treated with Cyramza plus FOLFIRI compared with 4 ( 4 % ) patients treated with placebo plus FOLFIRI .", "label": "", "metadata": {}, "score": "46.414444"}
{"text": "This study does show a potential benefit to combining anti - angiogenic agents with taxanes for metastatic breast cancer , however further follow up is needed to make conclusions regarding overall survival .", "label": "", "metadata": {}, "score": "46.600075"}
{"text": "Three patients were registered for the study but did not receive any chemotherapy or follow up staging studies ; therefore , they are considered neither r - e nor drug toxicity evaluable .", "label": "", "metadata": {}, "score": "46.609413"}
{"text": "The results of these trials have demonstrated the efficacy of gefitinib that can be now considered as the standard first - line treatment of patients with advanced NSCLC harbouring activating EGFR mutations .", "label": "", "metadata": {}, "score": "46.724747"}
{"text": "Patients with gastric cancer receiving nonsteroidal anti - inflammatory drugs ( NSAIDs ) were excluded from enrollment in Studies 1 and 2 ; therefore , the risk of gastric hemorrhage in Cyramza - treated patients with gastric tumors receiving NSAIDs is unknown .", "label": "", "metadata": {}, "score": "46.951256"}
{"text": "This is also supported by the serious adverse events observed ( see Table 3 ) .However , the number of patients is small and the results should therefore be interpreted with caution .", "label": "", "metadata": {}, "score": "46.953537"}
{"text": "Human Pharmacokinetics .Absorption : The pharmacokinetics of docetaxel have been evaluated in cancer patients after administration of 20 mg / m 2 to 115 mg / m 2 in phase 1 studies .", "label": "", "metadata": {}, "score": "47.17758"}
{"text": "Infusion - Related Reactions .Prior to the institution of premedication recommendations across clinical trials of Cyramza , IRRs occurred in 6 out of 37 patients ( 16 % ) , including two severe events .", "label": "", "metadata": {}, "score": "47.202568"}
{"text": "Two patients discontinued Cyramza due to proteinuria .The rate of gastrointestinal perforation in Study 1 was 0.8 % and the rate of infusion - related reactions was 0.4 % [ see Dosage and Administration ( 2.2 , 2.3 ) and Warnings and Precautions ( 5.4 , 5.5 ) ] .", "label": "", "metadata": {}, "score": "47.245895"}
{"text": "The response rate in the pretreated and untreated patients was 9 % and 17 % , respectively .Finally , a phase II trial investigated the activity of gefitinib 250 mg daily in 37 chemo - na\u00efve Korean patients with adenocarcinoma and a never - smoking history [ 56 ] .", "label": "", "metadata": {}, "score": "47.257816"}
{"text": "All these patients needed supportive hospitalization .For one patient in each treatment group , multiple SAEs were reported , with two events for the patient treated with gefitinib and three events for the placebo - treated patient .", "label": "", "metadata": {}, "score": "47.31441"}
{"text": "Efficacy results are shown in Table 6 and Figure 1 .Study 2 was a multinational , randomized , double - blind study of Cyramza plus paclitaxel versus placebo plus paclitaxel that randomized ( 1:1 ) 665 patients with locally advanced or metastatic gastric cancer ( including adenocarcinoma of the gastro - esophageal junction ) who previously received platinum- and fluoropyrimidine - containing chemotherapy .", "label": "", "metadata": {}, "score": "47.34464"}
{"text": "Docetaxel clearance was 17.9\u00b18.75 L / h / m 2 , corresponding to an AUC of 4.20\u00b12.57 \u03bcg.h / mL. In summary , the body surface area adjusted clearance of docetaxel monotherapy and TCF combination in children were comparable to those in adults [ see Clinical Pharmacology ( 12.3 ) ] .", "label": "", "metadata": {}, "score": "47.37849"}
{"text": "5 , pp .472 - 476 , 2004 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . D. Galetta , V. Gebbia , F. Giotta et al . , \" Gemcitabine and docetaxel every 2 weeks in advanced non - small cell lung cancer : a phase II study of the Gruppo Oncologico Italia Meridionale , \" Lung Cancer , vol .", "label": "", "metadata": {}, "score": "47.417763"}
{"text": "However , the clinical benefit ( PR + SD ) rate was 55 % .One proposed reason for the low response rate is the type of recurrent disease treated , as the majority of patients included in this trail had previous one to two lines of chemotherapy or concurrent chemo - irradiation with unresectable relapses in the radiation field .", "label": "", "metadata": {}, "score": "47.4449"}
{"text": "Docetaxel was administered q3 weeks for up to 9 cycles .BV / PL was administered until disease progression or limiting toxicity .The primary endpoint studied was PFS .", "label": "", "metadata": {}, "score": "47.513924"}
{"text": "Whether progression - free survival prolongation translates into survival gain is not yet clear : mature data from the IPASS trial showed no survival difference between first - line gefitinib and chemotherapy , probably due to treatment cross - over of patients with tumor harbouring EGFR mutation [ 61 ] .", "label": "", "metadata": {}, "score": "47.523674"}
{"text": "Two SNP rs701992 in NDUFB4 and rs1341164 in CYP2C8 were found weakly associated with WHO score at 0 and 8 weeks of treatment , respectively ( see supplementary Table 2 ) .", "label": "", "metadata": {}, "score": "47.534714"}
{"text": "Severity of neutropenia was grade 3 or 4 , affecting 43 and 49 % of the patients , respectively .In one of the studies , the patients were allowed to continue in the study until disease progression or other causes for withdrawal , and 30 % of the patients discontinued the treatment due to toxicity [ 12 ] .", "label": "", "metadata": {}, "score": "47.586838"}
{"text": "The institutional review board of the participating center approved the study , and all patients provided signed informed consent .Study Design and Treatment .This was a prospective , phase II evaluation of biweekly doses of gemcitabine and docetaxel .", "label": "", "metadata": {}, "score": "47.601425"}
{"text": "However , notably , among patients with EGFR mutation - positive tumors , PFS was longer ( HR 0.16 ; 95 % CI 0.05 - 0.49 , . ) and objective response was higher ( 42.1 % versus 9.8 % ) for gefitinib as compared to docetaxel .", "label": "", "metadata": {}, "score": "47.602856"}
{"text": "Patients were also required to have ECOG PS of 0 or 1 .Demographic and baseline characteristics were similar between treatment arms .The majority of patients ( 85 % ) experienced disease progression during or following first - line therapy for metastatic disease .", "label": "", "metadata": {}, "score": "47.704357"}
{"text": "Demographic and baseline characteristics were similar between treatment arms .Overall survival and progression - free survival were statistically significantly improved in patients randomized to receive Cyramza plus FOLFIRI compared to patients randomized to receive placebo plus FOLFIRI .", "label": "", "metadata": {}, "score": "47.722073"}
{"text": "Patients who discontinued combination therapy because of an adverse event attributed to either Cyramza / placebo or docetaxel were permitted to continue monotherapy with the other treatment component until disease progression or intolerable toxicity .", "label": "", "metadata": {}, "score": "47.766094"}
{"text": "Combination therapy with Taxotere in the adjuvant treatment of breast cancer .The following table presents treatment emergent adverse reactions observed in 744 patients , who were treated with Taxotere 75 mg / m 2 every 3 weeks in combination with doxorubicin and cyclophosphamide ( see Table 6 ) .", "label": "", "metadata": {}, "score": "47.855377"}
{"text": "On days 3 through 9 , 300 mg of G - CSF was administered .All patients received steroid prophylaxis in the form of 8 mg of dexamethasone twice daily , beginning the day before chemotherapy and continuing through day 4 .", "label": "", "metadata": {}, "score": "47.885918"}
{"text": "25 , pp .5892 - 5899 , 2005 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .K. Kelly , K. Chansky , L. E. Gaspar et al . , \" Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non - small - cell lung cancer : SWOG S0023 , \" Journal of Clinical Oncology , vol .", "label": "", "metadata": {}, "score": "47.888878"}
{"text": "Of note , there were no reports of grade 3 - 4 neuropathy .Time to Treatment Failure , Time to Progression , and Overall Survival .", "label": "", "metadata": {}, "score": "47.904495"}
{"text": "The primary endpoint was time to progression .The following table summarizes the study results ( See Table 12 ) .In a second randomized trial , patients previously treated with an alkylating - containing regimen were assigned to treatment with Taxotere ( 100 mg / m 2 ) or doxorubicin ( 75 mg / m 2 ) every 3 weeks .", "label": "", "metadata": {}, "score": "47.905777"}
{"text": "Phase III Clinical Studies in First - Line Therapy .Both of these studies failed to demonstrate any advantage in overall survival for patients treated with chemotherapy in combination with gefitinib .", "label": "", "metadata": {}, "score": "47.92325"}
{"text": "Secondary objectives are progression - free survival and safety profile .A phase IV study is investigating the activity and safety of gefitinib as first - line therapy for 100 Caucasian patients with EGFR - positive mutations ( ClinicalTrials.gov ID : NCT01203917 ) .", "label": "", "metadata": {}, "score": "48.03735"}
{"text": "However , G - CSF did shorten the duration of neutropenia from 7 to 9 days to 3 to 4 days .The ability of G - CSF to permit dosage escalation may depend on the setting .", "label": "", "metadata": {}, "score": "48.038162"}
{"text": "The reported WHO performance status was also worsened in patients treated with the chemotherapy / gefitinib combination .Whether this is due to the treatment is uncertain , as the time to tumor progression was shorter in the gefitinib / docetaxel treated patients , and a clinical deterioration may have resulted in a worsened performance status .", "label": "", "metadata": {}, "score": "48.048546"}
{"text": "Two - thirds of the patients experienced disease progression while on first - line therapy ( 67 % ) and 25 % of patients received an anthracycline in combination with platinum / fluoropyrimidine combination therapy .", "label": "", "metadata": {}, "score": "48.134354"}
{"text": "26 , pp .4244 - 4252 , 2008 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . D. H. Lee , K. Park , J. H. Kim et al . , \" Randomized phase III trial of gefitinib versus docetaxel in non - small cell lung cancer patients who have previously received platinum - based chemotherapy , \" Clinical Cancer Research , vol .", "label": "", "metadata": {}, "score": "48.179405"}
{"text": "The study also excluded patients whose only prior treatment for advanced NSCLC was a tyrosine kinase ( epidermal growth factor receptor [ EGFR ] or anaplastic lymphoma kinase [ ALK ] ) inhibitor .", "label": "", "metadata": {}, "score": "48.183662"}
{"text": "Discontinuation due to adverse reactions was reported in 5.3 % of patients treated with 60 mg / m 2 vs. 6.9 % and 16.5 % for patients treated at 75 mg / m 2 and 100 mg / m 2 respectively .", "label": "", "metadata": {}, "score": "48.23803"}
{"text": "357 , no .17 , pp .1705 - 1715 , 2007 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus Gefitinib in Combination with Weekly Docetaxel in Patients with Metastatic Breast Cancer Caused Unexpected Toxicity : Results from a Randomized Phase II Clinical Trial .", "label": "", "metadata": {}, "score": "48.23958"}
{"text": "Compare the overall survival of patients treated with these regimens .Compare the response rate in patients treated with these regimens .Compare the incidence of serious adverse events in patients treated with these regimens .", "label": "", "metadata": {}, "score": "48.281586"}
{"text": "Approximately 75 % of patients had died at the time of this analysis .Efficacy results are summarized in Table 19 and Figures 6 and 7 .", "label": "", "metadata": {}, "score": "48.31137"}
{"text": "Another randomized phase III trial is evaluating the efficacy of a maintenance therapy with gefitinib compared with placebo in 600 Japanese patients treated with first - line chemotherapy for stage IIIB or IV NSCLC ( ClinicalTrials.gov ID : NCT00144066 ) .", "label": "", "metadata": {}, "score": "48.33795"}
{"text": "Patients should be observed closely for hypersensitivity reactions , especially during the first and second infusions .Severe hypersensitivity reactions characterized by generalized rash / erythema , hypotension and/or bronchospasm , or very rarely fatal anaphylaxis , have been reported in patients premedicated with 3 days of corticosteroids .", "label": "", "metadata": {}, "score": "48.392277"}
{"text": "5 , pp .744 - 752 , 2010 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .R. Maruyama , Y. Nishiwaki , T. Tamura et al . , \" Phase III study , V-15 - 32 , of gefitinib versus docetaxel in previously treated Japanese patients with non - small - cell lung cancer , \" Journal of Clinical Oncology , vol .", "label": "", "metadata": {}, "score": "48.460526"}
{"text": "127 - 132 , 2005 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .G. Giaccone , R. S. Herbst , C. Manegold et al . , \" Gefitinib in combination with gemcitabine and cisplatin in advanced non - small - cell lung cancer : a phase III trial - INTACT 1 , \" Journal of Clinical Oncology , vol .", "label": "", "metadata": {}, "score": "48.545498"}
{"text": "Table 4 provides the frequency and severity of adverse reactions in Study 3 .Study 4 was a multinational , randomized , double - blind study conducted in patients with metastatic colorectal cancer with disease progression on or after therapy with bevacizumab , oxaliplatin , and a fluoropyrimidine .", "label": "", "metadata": {}, "score": "48.579082"}
{"text": "The study drugs were relatively safe , and the clinical benefit ( PR + SD ) rate was 55 % .However , the efficacy objective for this regimen was not met .", "label": "", "metadata": {}, "score": "48.67044"}
{"text": "9555 , pp .29 - 36 , 2007 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . D. J. Slamon , B. Leyland - Jones , S. Shak et al . , \" Use of chemotherapy plus a monoclonal antibody against her2 for metastatic breast cancer that overexpresses HER2 , \" The New England Journal of Medicine , vol .", "label": "", "metadata": {}, "score": "48.68394"}
{"text": "Combination Therapy with Strong CYP3A4 inhibitors : .Avoid using concomitant strong CYP3A4 inhibitors ( e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin and voriconazole ) .", "label": "", "metadata": {}, "score": "48.811882"}
{"text": "The median cumulative dose to onset of moderate or severe fluid retention was 819 mg / m 2 .Nine of 92 patients ( 9.8 % ) of patients discontinued treatment due to fluid retention : 4 patients discontinued with severe fluid retention ; the remaining 5 had mild or moderate fluid retention .", "label": "", "metadata": {}, "score": "48.853706"}
{"text": "The patient demography was similar in the gefitinib and placebo group , with respect to age and height / weight ( see Table 1 ) .", "label": "", "metadata": {}, "score": "48.884796"}
{"text": "The intrathoracic disease could have a different biologic behavior that should be further explored .Randomized Clinical Studies in Special Populations .In consideration of its good toxicity profile , gefitinib has been tested as an alternative to a single - agent chemotherapy in elderly and poor performance status ( PS ) NCSLC patients .", "label": "", "metadata": {}, "score": "48.88758"}
{"text": "Table 3 : Phase II trials with Gefitinib as single agent in \" selected \" patients with NSCLC .Phase III Clinical Studies .Four randomized phase III clinical trials evaluated the role of gefitinib as first line therapy of patients with advanced NSCLC , selected on the basis of clinical or molecular features ( Table 4 ) [ 57 - 60 ] .", "label": "", "metadata": {}, "score": "48.928467"}
{"text": "Only one patient had febrile neutropenia .Twenty - five ( 76 % ) patients received all treatments without a dose reduction and twenty - seven ( 82 % ) patients had no treatment interruption .", "label": "", "metadata": {}, "score": "49.00889"}
{"text": "23 , pp .1714 - 1723 , 2006 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . A. Tran , V. Jullien , J. Alexandre et al . , \" Pharmacokinetics and toxicity of docetaxel : role of CYP3A , MDR1 , and GST polymorphisms , \" Clinical Pharmacology and Therapeutics , vol . 79 , no .", "label": "", "metadata": {}, "score": "49.071663"}
{"text": "Endocrine level changes and the most common drug - related AEs were consistent with potent AR signaling inhibition .Title : Enzalutamide in combination with docetaxel in men with metastatic castration - resistant prostate cancer ( mCRPC ) : preliminary results from a phase 1 study ( Abstract # 63 ) .", "label": "", "metadata": {}, "score": "49.090477"}
{"text": "Patients and Methods .Patient Selection , Inclusion and Exclusion Criteria , and Randomization .The study was planned for the inclusion of 66 patients with metastatic breast cancer in a placebo - controlled double - blind randomized phase II clinical trial .", "label": "", "metadata": {}, "score": "49.23464"}
{"text": "Among patients who experienced treatment - related mortality at the 75 mg / m 2 dose level , 3 of 5 patients had an ECOG PS of 2 at study entry [ see Dosage and Administration ( 2.2 ) , Clinical Studies ( 14 ) ] .", "label": "", "metadata": {}, "score": "49.347588"}
{"text": "One patient out of 50 in the TCF group ( 2 % ) had a complete response while none of the 25 patients in the CF group had a complete response .", "label": "", "metadata": {}, "score": "49.35015"}
{"text": "A randomized phase III clinical study will compare gefitinib versus pemetrexed in never - smoker patients with adenocarcinoma histotype , previously treated with platinum - based chemotherapy ( ClinicalTrials.gov ID : NCT01066195 ) .", "label": "", "metadata": {}, "score": "49.440254"}
{"text": "Pharmacokinetic parameters for docetaxel were determined in 2 pediatric solid tumor trials .Following docetaxel administration at 55 mg / m 2 to 235 mg / m 2 in a 1-hour intravenous infusion every 3 weeks in 25 patients aged 1 to 20 years ( median 11 years ) , docetaxel clearance was 17.3\u00b110.9 L / h / m 2 .", "label": "", "metadata": {}, "score": "49.45023"}
{"text": "The primary endpoint was time to progression .The study results are summarized below ( See Table 13 ) .In this trial , 94 % of patients had metastatic disease and 79 % had received prior anthracycline therapy .", "label": "", "metadata": {}, "score": "49.482384"}
{"text": "Despite this , monotherapy inhibiting the EGF ( epidermal growth factor - erbB1 ) receptor with erlotinib or gefitinib in unselected breast cancer patients has been disappointing , without clinical efficacy [ 6 , 7 ] .", "label": "", "metadata": {}, "score": "49.536575"}
{"text": "This study demonstrates a clinical benefit in PFS and RR for the combination of bevacizumab and docetaxel as a 1 st line treatment for metastatic breast cancer patients .", "label": "", "metadata": {}, "score": "49.548904"}
{"text": "Prior to inclusion , patients were required not to have persistent adverse events ( common toxicity criteria ( CTC ) grade 3 or more ) from other anticancer treatments and should not have received other treatment modalities .", "label": "", "metadata": {}, "score": "49.583824"}
{"text": "In a study investigating the influence of 550 SNPs on docetaxel clearance in 24 patients with NSCLC treated at our institution , a number of SNPs were found to be associated with docetaxel clearance [ 26 ] .", "label": "", "metadata": {}, "score": "49.619316"}
{"text": "Response rate was 62.1 % and 32.2 % with gefitinib and chemotherapy , respectively ( . )Myelosuppression , alopecia and fatigue were more frequent in the cisplatin - docetaxel group , while skin toxicity , liver dysfunction , and diarrhea in the gefitinib group .", "label": "", "metadata": {}, "score": "49.669876"}
{"text": "However , despite an excellent safety profile of these agents when given alone , the addition of other therapies may change the tolerability of the chemotherapy treatment .", "label": "", "metadata": {}, "score": "49.781982"}
{"text": "[ 12 ] .Diarrhea and rash , the primary DLTs , occurred at 800 mg .Frequent treatment - related grade 1 - 2 adverse events were diarrhea ( 55 % ) , asthenia ( 44 % ) , and acne - like follicular rash ( 46 % ) .", "label": "", "metadata": {}, "score": "49.793236"}
{"text": "12 , pp .1545 - 1552 , 2007 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .G. Giaccone , R. S. Herbst , C. Manegold et al . , \" Gefitinib in combination with gemcitabine and cisplatin in advanced non - small - cell lung cancer : a phase III trial - INTACT 1 , \" Journal of Clinical Oncology , vol .", "label": "", "metadata": {}, "score": "49.84244"}
{"text": "In the chemotherapy of nine patients , four had a partial response and four stable disease .The breast cancer patients in this study were genotyped using a panel of 14 single - nucleotide polymorphisms ( SNPs ) , previously found associated with docetaxel clearance in a cohort of lung cancer patients .", "label": "", "metadata": {}, "score": "49.883007"}
{"text": "Of the two doublets , docetaxel combined with cisplatin appeared to be the more effective regimen in regard to both objective and complete responses [ 6 - 9 ] .", "label": "", "metadata": {}, "score": "49.92914"}
{"text": "The results of other phase 2 studies conducted with gefitinib as single agent in unselected patients with advanced NSCLC are summarized in Table 1 [ 15 - 23 ] .", "label": "", "metadata": {}, "score": "49.94648"}
{"text": "Two hundred three patients were randomized to Taxotere and 189 to the comparator arm .Most patients had received prior chemotherapy for metastatic disease ; only 27 patients on the Taxotere arm and 33 patients on the comparator arm entered the study following relapse after adjuvant therapy .", "label": "", "metadata": {}, "score": "50.006195"}
{"text": "Although neurotoxicity was generally a minor problem , one patient had grade 3 neurotoxicity .Seven patients ( 18 % ) had edema , but none developed clinically significant pleural effusion or required discontinuation of treatment due to fluid retention .", "label": "", "metadata": {}, "score": "50.169434"}
{"text": "6 , pp .545 - 551 , 2007 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .J. M. Nabholtz , H. J. Senn , W. R. Bezwoda , et al . , \" Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline - containing chemotherapy .", "label": "", "metadata": {}, "score": "50.18323"}
{"text": "Of the 563 Cyramza - treated patients in two randomized gastric cancer clinical studies , 36 % were 65 and over , while 7 % were 75 and over .", "label": "", "metadata": {}, "score": "50.289047"}
{"text": "These clinical studies of Taxotere in combination with cisplatin and fluorouracil in patients with SCCHN did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently from younger patients .", "label": "", "metadata": {}, "score": "50.308258"}
{"text": "The median number of cycles administered was 4 .Bone marrow suppression was the main toxicity .Ten ( 30 % ) patients had grade 3 - 4 neutropenia , 25 ( 76 % ) patients received all treatments without a dose reduction , and 27 ( 82 % ) patients had no treatment interruption .", "label": "", "metadata": {}, "score": "50.308693"}
{"text": "845 - 849 , 2000 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . A. D. Colevas , S. Adak , P. C. Amrein , J. J. Barton , R. Costello , and M. R. Posner , \" A phase II trial of palliative docetaxel plus 5-fluorouracil for squamous - cell cancer of the head and neck , \" Annals of Oncology , vol .", "label": "", "metadata": {}, "score": "50.339005"}
{"text": "In anthracycline - resistant patients , the overall response rate was 37.9 % ( 72/190 ; 95 % C.I. : 31.0 - 44.8 ) and the complete response rate was 2.1 % .", "label": "", "metadata": {}, "score": "50.36123"}
{"text": "6 , pp .543 - 547 , 1994 .View at Google Scholar \u00b7 View at Scopus .C. N. Rittenberg , R. J. Gralla , and J. T. Cole , \" Preventing docetaxel induced fluid retention : the efficacy of corticosteroids , \" in Proceedings of the American Society of Clinical Oncology ( ASCO ' 96 ) , vol .", "label": "", "metadata": {}, "score": "50.364388"}
{"text": "5 , pp .535 - 539 , 2000 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . D. Genet , D. Cupissol , N. Tubiana - Mathieu et al . , \" Docetaxel plus 5-fluorouracil in locally recurrent and/or metastatic squamous cell carcinoma of the head and neck : a phase II multicenter study , \" American Journal of Clinical Oncology , vol .", "label": "", "metadata": {}, "score": "50.418724"}
{"text": "Appropriate antiemetics were used as premedication as well as dexamethasone , either 8 mg PO BID starting one day before each dose of docetaxel for 3 days or as 20 mg IV prior to docetaxel infusion [ 20 ] .", "label": "", "metadata": {}, "score": "50.449715"}
{"text": "Toxicity with the docetaxel regimen given every third week is significant , and a better tolerated weekly dosing regimen has consequently been introduced [ 22 - 24 ] .", "label": "", "metadata": {}, "score": "50.498924"}
{"text": "In EGFR - mutated patients ( 66.8 % ) , the response rate was 62.5 % .The Southwest Oncology Group performed a phase II trial for pretreated ( . ) patients with bronchioalveolar carcinoma [ 55 ] .", "label": "", "metadata": {}, "score": "50.545845"}
{"text": "The current AVADO study was undertaken to examine the hypothesis that the addition of BV will also improve PFS in patients treated with docetaxel , as opposed to paclitaxel , as first line therapy in patients with locally recurrent or metastatic breast cancer .", "label": "", "metadata": {}, "score": "50.62288"}
{"text": "In the adjuvant breast cancer trial ( TAX316 ) , Taxotere in combination with doxorubicin and cyclophosphamide was administered to 744 patients of whom 48 ( 6 % ) were 65 years of age or greater .", "label": "", "metadata": {}, "score": "50.68348"}
{"text": "Effect of Ketoconazole : The effect of ketoconazole ( a strong CYP3A4 inhibitor ) on the pharmacokinetics of docetaxel was investigated in 7 cancer patients .", "label": "", "metadata": {}, "score": "50.71109"}
{"text": "compared gefitinib to BSC in 201 untreated NCSLC patients with . , not eligible for chemotherapy , in a randomized phase II trial [ 41 ] .", "label": "", "metadata": {}, "score": "50.775696"}
{"text": "Gefitinib has been successfully combined with other therapies ( hormonal therapy and chemotherapy ) , without severe combined toxicity [ 30 ] .Nevertheless , increased gastrointestinal toxicities and rash have been observed .", "label": "", "metadata": {}, "score": "50.799736"}
{"text": "Single Arm Studies .Taxotere at a dose of 100 mg / m 2 was studied in six single arm studies involving a total of 309 patients with metastatic breast cancer in whom previous chemotherapy had failed .", "label": "", "metadata": {}, "score": "50.862823"}
{"text": "Patients received a median of 8 doses ( range 1 - 68 ) of Cyramza ; the median duration of exposure was 4.4 months , and 169 ( 32 % of 529 ) patients received Cyramza for at least six months .", "label": "", "metadata": {}, "score": "50.874004"}
{"text": "In Study 4 , the incidence of severe bleeding was 2.5 % for Cyramza plus FOLFIRI and 1.7 % for placebo plus FOLFIRI .Permanently discontinue Cyramza in patients who experience severe bleeding [ see Dosage and Administration ( 2.3 ) ] .", "label": "", "metadata": {}, "score": "50.907074"}
{"text": "Patients in Study 2 received a median of 9 doses of Cyramza ; the median duration of exposure was 18 weeks , and 93 ( 28 % of 327 ) patients received Cyramza for at least six months .", "label": "", "metadata": {}, "score": "51.05959"}
{"text": "The development of gefitinib in NSCLC is a clear example of the difficulties in designing and conducting of clinical trials with new molecular - targeted agents and of the uncertainty about predictive factors and selection criteria [ 62 ] .", "label": "", "metadata": {}, "score": "51.07747"}
{"text": "View at Google Scholar .M. J. Piccart - Gebhart , M. Procter , B. Leyland - Jones et al . , \" Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer , \" The New England Journal of Medicine , vol .", "label": "", "metadata": {}, "score": "51.142345"}
{"text": "Phase I Clinical Studies .Gefitinib has been evaluated as single agent in four phase 1 clinical trials , including patients with advanced refractory solid tumors .", "label": "", "metadata": {}, "score": "51.160442"}
{"text": "The primary efficacy endpoint was overall survival .Treatment with Taxotere+cisplatin did not result in a statistically significantly superior survival compared to vinorelbine+cisplatin ( see table below ) .", "label": "", "metadata": {}, "score": "51.243412"}
{"text": "25 , pp .6117 - 6125 , 2005 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .I. Royer , B. Monsarrat , M. Sonnier , M. Wright , and T. Cresteil , \" Metabolism of docetaxel by human cytochromes P450 : interactions with paclitaxel and other antineoplastic drugs , \" Cancer Research , vol .", "label": "", "metadata": {}, "score": "51.29361"}
{"text": "26 , pp .4253 - 4260 , 2008 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .G. Goss , D. Ferry , R. Wierzbicki et al . , \" Randomized phase II study of gefitinib compared with placebo in chemotherapy - naive patients with advanced non - small - cell lung cancer and poor performance status , \" Journal of Clinical Oncology , vol .", "label": "", "metadata": {}, "score": "51.369118"}
{"text": "The primary endpoint was progression - free survival .The study met its endpoint , showing a median progression - free survival of 9.2 months in the gefitinib group versus 6.3 months in the chemotherapy group ( HR 0.489 , 95 % CI : 0.336 - 0.710 , . )", "label": "", "metadata": {}, "score": "51.388893"}
{"text": "However , associations between genetic variants of the CYP3A enzymes and the effect of docetaxel have not , to our knowledge , been found , although pharmacogenomic studies have been published investigating the possible influence of genetic variants on the docetaxel metabolism [ 38 - 40 ] .", "label": "", "metadata": {}, "score": "51.42305"}
{"text": "Protease inhibitors , particularly ritonavir , may increase the exposure of docetaxel .Concomitant use of Taxotere and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided .", "label": "", "metadata": {}, "score": "51.42636"}
{"text": "In case of grade 4 thrombocytopenia the Taxotere dose should be reduced from 75 mg / m 2 to 60 mg / m 2 .Discontinue treatment if these toxicities persist .", "label": "", "metadata": {}, "score": "51.435314"}
{"text": "For nonhematologic toxicities , however , although there were no incidences of grade 3/4 hand - foot syndrome in the gemcitabine group , there were 39 cases ( 26 % ) in the capecitabine group .", "label": "", "metadata": {}, "score": "51.47705"}
{"text": "5 , pp .785 - 794 , 2004 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .R. S. Herbst , D. Prager , R. Hermann et al . , \" TRIBUTE : a phase III trial of erlotinib hydrochloride ( OSI-774 ) combined with carboplatin and paclitaxel chemotherapy in advanced non - small - cell lung cancer , \" Journal of Clinical Oncology , vol .", "label": "", "metadata": {}, "score": "51.49576"}
{"text": "In this study , mutations were identified in 35 % of patients and 31 patients received gefitinib : the response rate was 55 % , the median progression - free survival was 9.2 months , and overall survival was 17.5 months .", "label": "", "metadata": {}, "score": "51.498085"}
{"text": "Severe proteinuria was reported in 3 % of patients treated with Cyramza plus FOLFIRI ( including 3 cases [ 0.6 % ] of nephrotic syndrome ) compared to 0.2 % of patients treated with placebo plus FOLFIRI .", "label": "", "metadata": {}, "score": "51.561745"}
{"text": "6 , pp .533 - 537 , 1994 .View at Google Scholar \u00b7 View at Scopus .C. Couteau , N. Chouaki , S. Leyvraz et al . , \" A phase II study of docetaxel in patients wtth metastatic squamous cell carcinoma of the head and neck , \" British Journal of Cancer , vol .", "label": "", "metadata": {}, "score": "51.58396"}
{"text": "In a study conducted in chemotherapy - na\u00efve patients with NSCLC ( TAX326 ) , 148 patients ( 36 % ) in the Taxotere+cisplatin group were 65 years of age or greater .", "label": "", "metadata": {}, "score": "51.789463"}
{"text": "In both cases there is a higher frequency of the mutated allele in the groups with higher scores for the clinical end - points .The genotype distribution of these SNPs associated with the WHO performance status at before treatment ( SNP rs701992 ) and after 8 weeks of therapy ( SNP rs1341164 ) can be found in supplementary Table 2 .", "label": "", "metadata": {}, "score": "51.91404"}
{"text": "4 , pp .438 - 443 , 2007 .View at Google Scholar \u00b7 View at Scopus .R. C. Shepard , D. Levy , J. D. Berlin et al . , \" Phase II study of gemcitabine in combination with docetaxel in patients with advanced pancreatic carcinoma ( E1298 ) : a trial of the Eastern Cooperative Oncology Group , \" Oncology , vol .", "label": "", "metadata": {}, "score": "51.9353"}
{"text": "However , enhanced efficacy of chemotherapy when combined with EGFr inhibition has been described in an experimental setting [ 9 ] and such treatment may even result in an antiangiogenic effect [ 10 ] .", "label": "", "metadata": {}, "score": "51.975998"}
{"text": "Despite this , patients who discontinued due to toxicity were present in each group ( four in the placebo - treated group at 3.4 , 13.4 , 18 , and 22 weeks , and three in the gefitinib group at 2 , 5 , and 19.7 weeks ) .", "label": "", "metadata": {}, "score": "52.08023"}
{"text": "Moreover , clinical and demographic factors , including female sex , nonsmoking status , adenocarcinoma histotype , and Asian race have been identified as potentially predictive of the efficacy of EGFR tyrosine kinase inhibitors .", "label": "", "metadata": {}, "score": "52.164955"}
{"text": "Pharmacokinetic parameters estimated by this analysis were very close to those estimated from phase 1 studies .The pharmacokinetics of docetaxel were not influenced by age .", "label": "", "metadata": {}, "score": "52.182823"}
{"text": "The efficacy and safety of XTANDI were assessed in the randomized , placebo - controlled , global phase 3 AFFIRM clinical trial .Patients with a history of seizure , taking medications known to decrease the seizure threshold , or with other risk factors for seizure were excluded from the clinical trial .", "label": "", "metadata": {}, "score": "52.21354"}
{"text": "No bias was found with regards to treatment regimen or clinical end - points ( toxic reaction , WHO score , and treatment response - PR , SD , or PD ) .", "label": "", "metadata": {}, "score": "52.24449"}
{"text": "11 , pp .1604 - 1609 , 2006 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . S. K. Dennison , S. A. Jacobs , J. W. Wilson et al . , \" A phase II clinical trial of ZD1839 ( Iressa ) in combination with docetaxel as first - line treatment in patients with advanced breast cancer , \" Investigational New Drugs , vol .", "label": "", "metadata": {}, "score": "52.303123"}
{"text": "References .Lavelle F , Bissery MC , Combeau C , et al : Preclinical evaluation of docetaxel ( Taxotere ) .Semin Oncol 22(suppl 4):3 - 16 , 1995 .", "label": "", "metadata": {}, "score": "52.32631"}
{"text": "Pharmacokinetic analyses showed no apparent pharmacokinetic interaction between gefitinib and cisplatin or gemcitabine , with the exception of a possible small increase in the geometric mean exposure to gemcitabine seen on day 8 of therapy when given alone with the higher dose of gefitinib .", "label": "", "metadata": {}, "score": "52.333633"}
{"text": "Nursing Mothers .It is not known whether docetaxel is excreted in human milk .Pediatric Use .The efficacy of Taxotere in pediatric patients as monotherapy or in combination has not been established .", "label": "", "metadata": {}, "score": "52.360226"}
{"text": "107 - 116 , 1999 .View at Google Scholar \u00b7 View at Scopus .B. S. Glisson , B. A. Murphy , G. Frenette , F. R. Khuri , and A. A. Forastiere , \" Phase II trial of docetaxel and cisplatin combination chemotherapy in patients with squamous cell carcinoma of the head and neck , \" Journal of Clinical Oncology , vol .", "label": "", "metadata": {}, "score": "52.44409"}
{"text": "Patients with advanced SCCHN previously pretreated with one or two lines of palliative chemotherapy were treated with gemcitabine and docetaxel until disease progression .Results .", "label": "", "metadata": {}, "score": "52.47864"}
{"text": "Most of these patients had been heavily pretreated .Toxicity .The major toxicity was febrile neutropenia , defined as grade 3 or 4 neutropenia with fever , requiring intravenous antibiotics with or without hospitalization .", "label": "", "metadata": {}, "score": "52.482407"}
{"text": "Among 2045 patients with solid tumors and normal baseline LFTs , severe neutropenia occurred in 75.4 % and lasted for more than 7 days in 2.9 % of cycles .", "label": "", "metadata": {}, "score": "52.4852"}
{"text": "If symptoms persist , treatment should be discontinued [ see Dosage and Administration ( 2.7 ) ] .Patients who experienced neurotoxicity in clinical trials and for whom follow - up information on the complete resolution of the event was available had spontaneous reversal of symptoms with a median of 9 weeks from onset ( range : 0 to 106 weeks ) .", "label": "", "metadata": {}, "score": "52.512077"}
{"text": "In the second study ( TAX320 ) the rate of survival at one year favored Taxotere 75 mg / m 2 .Patients treated with Taxotere at a dose of 75 mg / m 2 experienced no deterioration in performance status and body weight relative to the comparator arms used in these trials .", "label": "", "metadata": {}, "score": "52.51228"}
{"text": "They could also receive adjuvant chemotherapy as appropriate .The primary end - point was overall survival .The study planned to enrol 1160 patients , but it was stopped prematurely in 2005 , following the negative results of the ISEL study [ 30 ] and the SWOG S0023 trials [ 39 ] .", "label": "", "metadata": {}, "score": "52.608402"}
{"text": "Experience has shown that premedication with dexamethasone reduces toxicity due to fluid retention .[ 8 ] In this study , all patients received steroid prophylaxis , and there was no clinically significant pleural effusion in any patient .", "label": "", "metadata": {}, "score": "52.61464"}
{"text": "21 , pp .3340 - 3346 , 2006 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .C. H. Yang , C. J. Yu , J. Y. Shih et al . , \" Specific EGFR mutations predict treatment outcome of stage IIIB / IV patients with chemotherapy - naive non - small - cell lung cancer receiving first - line gefitinib monotherapy , \" Journal of Clinical Oncology , vol .", "label": "", "metadata": {}, "score": "52.674202"}
{"text": "Both patients experienced severe neutropenia , mild asthenia , cutaneous reactions , and mild paresthesia , and recovered without incident .In male and female rats , lethality was observed at a dose of 20 mg / kg ( comparable to the human dose of 100 mg / m 2 on a mg / m 2 basis ) and was associated with abnormal mitosis and necrosis of multiple organs .", "label": "", "metadata": {}, "score": "52.69404"}
{"text": "Warnings and Precautions-In the randomized clinical trial , seizure occurred in 0.9 % of patients on XTANDI .No patients on the placebo arm experienced seizure .", "label": "", "metadata": {}, "score": "52.84147"}
{"text": "12 , pp .1545 - 1552 , 2007 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .R. S. Herbst , D. Prager , R. Hermann et al . , \" TRIBUTE : a phase III trial of erlotinib hydrochloride ( OSI-774 ) combined with carboplatin and paclitaxel chemotherapy in advanced non - small - cell lung cancer , \" Journal of Clinical Oncology , vol .", "label": "", "metadata": {}, "score": "52.849056"}
{"text": "The addition of BV added limited toxicity relative to the control group ; however , no serious adverse events ( grade 4 or 5 ) were reported .", "label": "", "metadata": {}, "score": "52.997208"}
{"text": "Proc Am Soc Clin Oncol 12:64 , 1993 .Chevallier B , Fumoleau P , Kerbrat P , et al : Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer : A phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment for Cancer .", "label": "", "metadata": {}, "score": "53.065273"}
{"text": "The most frequent adverse events were acne - like rash ( 64 % ) and diarrhea ( 47 % ) , which were generally mild ( grade 1/2 ) and reversible on cessation of treatment .", "label": "", "metadata": {}, "score": "53.091934"}
{"text": "In vivo studies showed that gefitinib had a favourable tolerability profile and an antitumor activity in various xenograft models and enhanced the antitumor activity of a variety of cytotoxic drugs , including platinum compounds [ 7 , 8 ] .", "label": "", "metadata": {}, "score": "53.14007"}
{"text": "Although the majority of the toxicity most likely is due to the chemotherapy treatment alone , treatment with gefitinib may have contributed and aggravated the toxicity .", "label": "", "metadata": {}, "score": "53.145355"}
{"text": "Patients in Study 1 received a median of 4 doses of Cyramza ; the median duration of exposure was 8 weeks , and 32 ( 14 % of 236 ) patients received Cyramza for at least six months .", "label": "", "metadata": {}, "score": "53.149605"}
{"text": "There was no difference seen in HTN , GI perforation , or thromoembolic events between the various arms .The incidence of febrile neutropenia was increased in the BV arms compared to the placebo arm ; however , anemia and infection rates were higher in the control group .", "label": "", "metadata": {}, "score": "53.195515"}
{"text": "Hematologic Toxicity .Biweekly gemcitabine and docetaxel ( GEMDOC ) was generally well tolerated ( Table 3 ) .There were no treatment - related deaths .", "label": "", "metadata": {}, "score": "53.240616"}
{"text": "Finally , exploratory analyses showed no difference between patients with high and low EGFR copy number within the gefitinib arm ( high versus low HR , 1.02 , 95 % CI 0.74 - 1.41 , . ) and no significant differences in survival outcome between the study arms according to KRAS mutation status .", "label": "", "metadata": {}, "score": "53.266155"}
{"text": "Patients and Methods .Patients .Patients with recurrent or metastatic histologically proven SCCHN who had received 1 to no more than 2 prior chemotherapy regimens were eligible .", "label": "", "metadata": {}, "score": "53.31207"}
{"text": "Two randomized phase 3 studies have been performed in Japanese , EGFR - mutated patients with advanced NSCLC , to compare the efficacy of gefitinib versus chemotherapy in the first - line setting .", "label": "", "metadata": {}, "score": "53.445976"}
{"text": "Patients who experience severe or cumulative cutaneous reactions or moderate neurosensory signs and/or symptoms during Taxotere therapy should have their dosage of Taxotere reduced from 75 mg / m 2 to 60 mg / m 2 .", "label": "", "metadata": {}, "score": "53.460403"}
{"text": "The results showed no statistical difference in progression - free survival ( 2.7 versus 2.9 months , HR 1.19 , 95 % CI , 0.85 - 1.65 , . ) , overall survival ( 5.9 versus 8.0 months ; HR 0.98 , 95 % CI , 0.66 - 1.47 ) , and response rate ( 3.1 versus 5.1 % ) between gefitinib and vinorelbine , respectively .", "label": "", "metadata": {}, "score": "53.4696"}
{"text": "Table 11 - Clinically Important Treatment Emergent Adverse Reactions ( Regardless of Relationship ) in Patients with SCCHN Receiving Induction Chemotherapy with Taxotere in Combination with cisplatin and fluorouracil followed by radiotherapy ( TAX323 ) or chemoradiotherapy ( TAX324 ) .", "label": "", "metadata": {}, "score": "53.49466"}
{"text": "22 - 28 , 2007 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .N. Sunaga , Y. Tomizawa , N. Yanagitani et al . , \" Phase II prospective study of the efficacy of gefitinib for the treatment of stage III / IV non - small cell lung cancer with EGFR mutations , irrespective of previous chemotherapy , \" Lung Cancer , vol .", "label": "", "metadata": {}, "score": "53.504177"}
{"text": "Drug Interactions .No pharmacokinetic interactions were observed between ramucirumab and paclitaxel , between ramucirumab and docetaxel , or between ramucirumab and irinotecan or its active metabolite , SN-38 [ see Clinical Pharmacology ( 12.3 ) ] .", "label": "", "metadata": {}, "score": "53.519615"}
{"text": "NCT Number ICMJE .NCT00075374 .Other Study ID Numbers ICMJE .MSMC1503 , CWRU - MSMC-1503 , AVENTIS - GIA-12143 , THERADEX - GIA-12143 , MTSMC - LUN06 Randomised , double - blind , placebo controlled , phase III study of bevacizumab ( BV ) with docetaxel ( D ) or docetaxel with placebo ( PL ) as first line therapy for patients with locally recurrent or metastatic breast cancer ( mBC ) : AVADO .", "label": "", "metadata": {}, "score": "53.530098"}
{"text": "This average , however , includes a substantial range and there is , at present , no measurement that would allow recommendation for dose adjustment in such patients .", "label": "", "metadata": {}, "score": "53.538414"}
{"text": "64 , no . 3 , pp .314 - 318 , 2009 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . A. Inoue , K. Kobayashi , K. Usui et al . , \" First - line gefitinib for patients with advanced non - small - cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy , \" Journal of Clinical Oncology , vol .", "label": "", "metadata": {}, "score": "53.56429"}
{"text": "View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . H. J. Burstein , J. Manola , J. Younger et al . , \" Docetaxel administered on a weekly basis for metastatic breast cancer , \" Journal of Clinical Oncology , vol .", "label": "", "metadata": {}, "score": "53.62247"}
{"text": "Nevertheless , toxicity was aggravated by the addition of the tyrosine kinase inhibitor .In conclusion , despite adequately tolerated as monotherapy , combination regimens should be carefully considered for overlapping adverse events in order to avoid increased treatment - related toxicity .", "label": "", "metadata": {}, "score": "53.642586"}
{"text": "As the authors note in their conclusions , this study is the first randomized phase III trial showing a benefit of the addition on BV to docetaxel in the treatment of metastatic breast cancer .", "label": "", "metadata": {}, "score": "53.65043"}
{"text": "Two patients died in each arm within 30 days of their last study treatment ; 1 death per arm was attributed to study drugs .Fever and Infection .", "label": "", "metadata": {}, "score": "53.655598"}
{"text": "Development of Gefitinib in \" Unselected \" Patients .Phase II Clinical Studies .Two randomized phase 2 clinical studies evaluated the safety and the activity of two doses of gefitinib ( 250 mg or 500 mg ) as second- or third - line therapy of NSCLC patients ( IDEAL 1 and IDEAL 2 ) [ 15 , 16 ] .", "label": "", "metadata": {}, "score": "53.661064"}
{"text": "15 , pp .2450 - 2456 , 2008 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .L. Crin\u00f2 , F. Cappuzzo , P. Zatloukal et al . , \" Gefitinib versus vinorelbine in chemotherapy - naive elderly patients with advanced non - small - cell lung cancer ( INVITE ) : a randomized , phase II study , \" Journal of Clinical Oncology , vol .", "label": "", "metadata": {}, "score": "53.742844"}
{"text": "As with all therapeutic proteins , there is the potential for immunogenicity .In 23 clinical trials , 86/2890 ( 3.0 % ) of Cyramza - treated patients tested positive for treatment - emergent anti - ramucirumab antibodies by an enzyme - linked immunosorbent assay ( ELISA ) .", "label": "", "metadata": {}, "score": "53.747894"}
{"text": "Moreover , it should be considered that , for patients who do not receive first - line tyrosine kinase inhibitors , there is the risk of never receiving an EGFR inhibitor at the time of disease progression , due to a rapid worsening of clinical conditions .", "label": "", "metadata": {}, "score": "53.774418"}
{"text": "Complete blood counts and serum biochemical assessments were performed every 2 weeks throughout the study .The severity of adverse events was graded according to the Common Toxicity Criteria Version 2.0 of the National Cancer Institute .", "label": "", "metadata": {}, "score": "53.776215"}
{"text": "In Study 4 , the incidence of gastrointestinal perforation was 1.7 % for Cyramza plus FOLFIRI and 0.6 % for placebo plus FOLFIRI .Permanently discontinue Cyramza in patients who experience a gastrointestinal perforation [ see Dosage and Administration ( 2.3 ) ] .", "label": "", "metadata": {}, "score": "53.7881"}
{"text": "In both trials , an attempt has been made to identify predictive factors for objective response to gefitinib .In the IDEAL-1 study , a multivariate analysis showed that performance status , previous immuno / hormonal treatment , histology , and female gender were significantly associated with a higher response rate , while in the IDEAL-2 study only female gender was significantly predictive of response to gefitinib .", "label": "", "metadata": {}, "score": "53.8445"}
{"text": "5 , pp .1234 - 1242 , 2010 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .M. N. Dickler , M. A. Cobleigh , K. D. Miller , P. M. Klein , and E. P. Winer , \" Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer , \" Breast Cancer Research and Treatment , vol .", "label": "", "metadata": {}, "score": "53.87561"}
{"text": "6 , pp .406 - 411 , 2006 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .R. Suzuki , Y. Hasegawa , K. Baba et al . , \" A phase II study of single - agent gefitinib as first - line therapy in patients with stage IV non - small - cell lung cancer , \" British Journal of Cancer , vol .", "label": "", "metadata": {}, "score": "53.898026"}
{"text": "64 - 69 , 2006 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .M. Reck , E. Buchholz , K. S. Romer , et al . , \" Gefitinib monotherapy in chemotherapy - naive patients with inoperable stage III / IV non - small - cell lung cancer , \" Clinical Lung Cancer , vol .", "label": "", "metadata": {}, "score": "53.91114"}
{"text": "Serious , sometimes fatal , arterial thromboembolic events ( ATEs ) including myocardial infarction , cardiac arrest , cerebrovascular accident , and cerebral ischemia occurred in clinical trials including 1.7 % of 236 patients who received Cyramza as a single agent for gastric cancer in Study 1 .", "label": "", "metadata": {}, "score": "53.942688"}
{"text": "5 , pp .1672 - 1678 , 1996 .View at Google Scholar \u00b7 View at Scopus .G. Catimel , J. Verweij , V. Mattijssen et al . , \" Docetaxel ( Taxotere ) : an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck , \" Annals of Oncology , vol .", "label": "", "metadata": {}, "score": "53.977806"}
{"text": "5 , pp .785 - 794 , 2004 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . U.Gatzemeier , A. Pluzanska , A. Szczesna et al . , \" Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non - small - cell lung cancer : the Tarceva lung cancer investigation trial , \" Journal of Clinical Oncology , vol .", "label": "", "metadata": {}, "score": "54.064117"}
{"text": "Efficacy results are shown in Table 9 and Figure 4 .Patient Counseling Information .Hemorrhage : Advise patients that Cyramza can cause severe bleeding .", "label": "", "metadata": {}, "score": "54.09187"}
{"text": "Recommended dose modifications for toxicities in patients treated with Taxotere in combination with cisplatin and fluorouracil are shown in Table 1 .First episode : reduce Taxotere and fluorouracil doses by 20 % .", "label": "", "metadata": {}, "score": "54.110256"}
{"text": "Dose escalation started at 50 mg and continued to 925 mg or until consistent dose - limiting toxicity ( DLT ) .Sixty - four patients were entered at eight dose levels .", "label": "", "metadata": {}, "score": "54.14098"}
{"text": "24 , pp .5552 - 5559 , 2005 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .W. P. Petros , P. J. Hopkins , S. Spruill et al . , \" Associations between drug metabolism genotype , chemotherapy pharmacokinetics , and overall survival in patients with breast cancer , \" Journal of Clinical Oncology , vol .", "label": "", "metadata": {}, "score": "54.19615"}
{"text": "Cisplatin and Fluorouracil : The combined administration of docetaxel , cisplatin and fluorouracil in 12 patients with solid tumors had no influence on the pharmacokinetics of each individual drug .", "label": "", "metadata": {}, "score": "54.19725"}
{"text": "One can hypothesize that since paclitaxel is given more often , there may be a \" dual hit \" on the tumor cells when both drugs are administered .", "label": "", "metadata": {}, "score": "54.19867"}
{"text": "16 , pp .2248 - 2255 , 2007 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . H. L. West , W. A. Franklin , J. McCoy et al . , \" Gefitinib therapy in advanced bronchioloalveolar carcinoma : Southwest Oncology Group study S0126 , \" Journal of Clinical Oncology , vol .", "label": "", "metadata": {}, "score": "54.200085"}
{"text": "On the basis of the lack of survival benefit in the ISEL study , in 2005 the FDA restricted the use of gefitinib to patients continuing to benefit from treatment already initiated or participating in clinical trials .", "label": "", "metadata": {}, "score": "54.20897"}
{"text": "The coprimary endpoints were the noninferiority of gefitinib in comparison with docetaxel in terms of overall survival in the total population and the superiority in patients expressing a high EGFR gene copy number .", "label": "", "metadata": {}, "score": "54.22818"}
{"text": "Pharmacokinetics .The pharmacokinetic ( PK ) characteristics of ramucirumab are similar for patients with gastric cancer , NSCLC , and mCRC based on a population PK analysis .", "label": "", "metadata": {}, "score": "54.229214"}
{"text": "Severe reactions occurred in 3 - 5 % of patients with solid tumors and to a similar extent among metastatic breast cancer patients .The incidence of severe reactions was 1 % or less for the 92 breast cancer patients premedicated with 3-day corticosteroids .", "label": "", "metadata": {}, "score": "54.236298"}
{"text": "All seizures resolved .Patients with a history of seizure , taking medications known to decrease the seizure threshold , or with other risk factors for seizure were excluded from the clinical trial .", "label": "", "metadata": {}, "score": "54.27558"}
{"text": "Dose reductions due to hematologic toxicity occurred in 1 % of cycles in the TAC arm versus 0.1 % of cycles in the FAC arm .", "label": "", "metadata": {}, "score": "54.288494"}
{"text": "Grade 3/4 fever in the absence of infection was seen in 1.3 % and 0 % of TAC- and FAC - treated patients respectively .Infection was seen in 39.4 % of TAC - treated patients compared to 36.3 % of FAC - treated patients .", "label": "", "metadata": {}, "score": "54.31318"}
{"text": "Multiple investigators have evaluated the combination of gemcitabine and docetaxel ( GEMDOC ) in phase II clinical trials on biweekly bases .[ 11 - 14 ] Previous phase II studies of biweekly GEMDOC have included patients with non - small - cell lung cancer , breast cancer , and pancreatic cancer and are summarized in Table 1 .", "label": "", "metadata": {}, "score": "54.337074"}
{"text": "View at Google Scholar . A. I. Dreyfuss , J. R. Clark , C. M. Norris et al . , \" Docetaxel : an active drug for squamous cell carcinoma of the head and neck , \" Journal of Clinical Oncology , vol .", "label": "", "metadata": {}, "score": "54.397438"}
{"text": "The 6-month TTP rate was 17 % ( 95 % CI : 1 - 32 % ) .Figure 2 : Kaplan - Meier plot of overall survival ( OS ) in 36 patients treated with biweekly gemcitabine and docetaxel .", "label": "", "metadata": {}, "score": "54.414764"}
{"text": "Dosage was escalated in seven levels , from 60 to 85 mg / m\u00b2 docetaxel and from 600 to 800 mg / m\u00b2cyclophosphamide ( Table 1 ) .", "label": "", "metadata": {}, "score": "54.441223"}
{"text": "Colorectal Cancer .Study 4 was a multinational , randomized , double - blind , study of Cyramza plus FOLFIRI versus placebo plus FOLFIRI , in patients with mCRC , who had disease progression on or after prior therapy with bevacizumab , oxaliplatin , and a fluoropyrimidine .", "label": "", "metadata": {}, "score": "54.481865"}
{"text": "[ see Clinical Studies ( 14.1 ) ] .Of the 1253 patients in Study 3 , 455 ( 36 % ) were 65 and over and 84 ( 7 % ) were 75 and over .", "label": "", "metadata": {}, "score": "54.485325"}
{"text": "Blogs .Taxotere .WARNING : TOXIC DEATHS , HEPATOTOXICITY , NEUTROPENIA , HYPERSENSITIVITY REACTIONS , and FLUID RETENTION .Patients with elevations of bilirubin or abnormalities of transaminase concurrent with alkaline phosphatase are at increased risk for the development of grade 4 neutropenia , febrile neutropenia , infections , severe thrombocytopenia , severe stomatitis , severe skin toxicity , and toxic death .", "label": "", "metadata": {}, "score": "54.628548"}
{"text": "Avoid CYP3A4 , CYP2C9 and CYP2C19 substrates with a narrow therapeutic index , as XTANDI may decrease the plasma exposures of these drugs .If XTANDI is co - administered with warfarin ( CYP2C9 substrate ) , conduct additional INR monitoring .", "label": "", "metadata": {}, "score": "54.655952"}
{"text": "Twenty - two percent of patients received prior maintenance therapy .Tumor EGFR status was unknown for the majority of patients ( 65 % ) .", "label": "", "metadata": {}, "score": "54.66646"}
{"text": "The study was stopped by independent data and safety monitoring committee after the preplanned interim analysis , conducted 4 months after the 200th patient enrolled , because it showed a significant difference in progression - free survival between the two treatment groups .", "label": "", "metadata": {}, "score": "54.698303"}
{"text": "To note , 22 of 30 patients had very poor PS ( 3 or 4 ) .The overall response rate was 66 % , with disease stabilization rate of 90 % .", "label": "", "metadata": {}, "score": "54.71808"}
{"text": "Capecitabine - treated patients had significantly less hematologic toxicity .Dr. Chan reported the results of a European phase III study comparing the two regimens as first - line or second- line treatment for patients with anthracycline - pretreated metastatic breast cancer .", "label": "", "metadata": {}, "score": "54.721397"}
{"text": "Combination therapy with Taxotere in patients with prostate cancer .The following data are based on the experience of 332 patients , who were treated with Taxotere 75 mg / m 2 every 3 weeks in combination with prednisone 5 mg orally twice daily ( see Table 9 ) .", "label": "", "metadata": {}, "score": "54.74018"}
{"text": "[ ONCOLOGY 11(Suppl 6):21 - 23 , 1997 ] .Introduction .Preclinical data demonstrate in vitro synergy for combinations of docetaxel ( Taxotere ) and cyclophosphamide ( Cytoxan , Neosar ) .", "label": "", "metadata": {}, "score": "54.76631"}
{"text": "JCO , 1998 ) was maintained .The efficacy data for the Taxotere+cisplatin arm and the comparator arm are summarized in Table 16 .Secondary endpoints evaluated in the trial included objective response and time to progression .", "label": "", "metadata": {}, "score": "54.910904"}
{"text": "[ see Clinical Studies ( 14.2 ) ] .Of the 529 patients who received Cyramza plus FOLFIRI in Study 4 , 209 ( 40 % ) were 65 and over , while 51 ( 10 % ) were 75 and over .", "label": "", "metadata": {}, "score": "54.918648"}
{"text": "Two patients developed DLT : one grade 3 convulsion ( 250 mg / day dose group ) and one grade 3 rash ( 500 mg / day dose group ) .", "label": "", "metadata": {}, "score": "54.940914"}
{"text": "3159 - 3167 , 2000 .View at Google Scholar \u00b7 View at Scopus . A. E. Wakeling , S. P. Guy , J. R. Woodburn et al . , \" ZD1839 ( Iressa ) : an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy , \" Cancer Research , vol .", "label": "", "metadata": {}, "score": "55.079422"}
{"text": "Another important finding of this study was the significant interaction between treatment efficacy and EGFR mutational status .In the subgroup of patients with EGFR mutation ( 261 of 437 available samples ) , progression - free survival was significantly longer ( HR 0.48 ; 95 % CI 0.36 - 0.64 , . )", "label": "", "metadata": {}, "score": "55.08788"}
{"text": "If an episode of febrile neutropenia , prolonged neutropenia or neutropenic infection occurs despite G - CSF use , the Taxotere dose should be reduced from 75 mg / m 2 to 60 mg / m 2 .", "label": "", "metadata": {}, "score": "55.110973"}
{"text": "The amplification of the Her2/neu oncogene with c - erbB2 overexpression in a subset of breast cancer patients is an example of this [ 2 - 4 ] .", "label": "", "metadata": {}, "score": "55.124706"}
{"text": "In this single - institution phase II trial , patients with recurrent or metastatic SCCHN were treated with the biweekly combination of gemcitabine and docetaxel ( GEMDOC ) after the failure of at least one prior chemotherapy regimen .", "label": "", "metadata": {}, "score": "55.140713"}
{"text": "Median overall survival with a median follow - up of 51.2 months was also significantly longer in favor of the TPF arm compared to the PF arm ( median OS : 18.6 vs. 14.2 months respectively ) .", "label": "", "metadata": {}, "score": "55.17549"}
{"text": "Clinical deterioration , manifested by new onset or worsening encephalopathy , ascites , or hepatorenal syndrome was reported in patients with Child - Pugh B or C cirrhosis who received single - agent Cyramza .", "label": "", "metadata": {}, "score": "55.235172"}
{"text": "20 , pp .1530 - 1533 , 1994 .View at Google Scholar \u00b7 View at Scopus .G. Catimel , J. B. Vermorken , M. Clavel et al . , \" A phase II study of Gemcitabine ( LY 188011 ) in patients with advanced squamous cell carcinoma of the head and neck , \" Annals of Oncology , vol .", "label": "", "metadata": {}, "score": "55.30328"}
{"text": "XTANDI can be taken with or without food and does not require concomitant steroid ( e.g. , prednisone ) use .In the phase 3 clinical trial , 48 % of XTANDI patients and 46 % of patients in the placebo arm were treated with glucocorticoids .", "label": "", "metadata": {}, "score": "55.337475"}
{"text": "Hematologic and other toxicity is increased at higher doses and in patients with elevated baseline liver function tests ( LFTs ) .Table 4 - Hematologic Adverse Reactions in Breast Cancer Patients Previously Treated with Chemotherapy Treated at Taxotere 100 mg / m 2 with Normal or Elevated Liver Function Tests or 60 mg / m 2 with Normal Liver Function Tests .", "label": "", "metadata": {}, "score": "55.371582"}
{"text": "The ONCOBELL trial enrolled 42 patients who were never smokers or who had evidence of a high EGFR gene copy on FISH and were p - AKT positive [ 54 ] .", "label": "", "metadata": {}, "score": "55.396034"}
{"text": "Most of the enrolled patients were male ( 77 % ) , smokers ( 82 % ) , and with squamous cell carcinoma , thus without clinical features conferring sensitivity to gefitinib , and this may explain the low percentage of responders in this study .", "label": "", "metadata": {}, "score": "55.41448"}
{"text": "20 , pp .5749 - 5754 , 2002 .View at Google Scholar \u00b7 View at Scopus . F. Ciardiello , R. Caputo , R. Bianco et al . , \" Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 ( Iressa ) , an epidermal growth factor receptor - selective tyrosine kinase inhibitor , \" Clinical Cancer Research , vol .", "label": "", "metadata": {}, "score": "55.420937"}
{"text": "15 , no .5 , pp .831 - 838 , 2004 .View at Publisher \u00b7 View at Google Scholar .M. Fukuoka , S. Yano , G. Giaccone et al . , \" Multi - institutional randomized phase II trial of gefitinib for previously treated patients with advanced non - small - cell lung cancer ( The IDEAL 1 Trial ) , \" Journal of Clinical Oncology , vol .", "label": "", "metadata": {}, "score": "55.429718"}
{"text": "Febrile neutropenia with or without infection was observed in 16 ( 41 % ) of the 38 patients and 25 ( 13 % ) of the 175 cycles .", "label": "", "metadata": {}, "score": "55.438522"}
{"text": "165 - 172 , 2005 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .J. Baselga , J. Albanell , A. Ruiz , et al . , \" Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer , \" Journal of Clinical Oncology , vol .", "label": "", "metadata": {}, "score": "55.552197"}
{"text": "CLINICAL STUDIES .Locally Advanced or Metastatic Breast Cancer .The efficacy and safety of Taxotere have been evaluated in locally advanced or metastatic breast cancer after failure of previous chemotherapy ( alkylating agent - containing regimens or anthracycline - containing regimens ) .", "label": "", "metadata": {}, "score": "55.603233"}
{"text": "The fourth phase 1 study investigated the tolerability and toxicity of gefitinib in Japanese patients with solid tumors [ 13 ] .Thirty - one patients were included and received oral gefitinib on 14 consecutive days , every 28 days .", "label": "", "metadata": {}, "score": "55.61386"}
{"text": "Median overall survival and progression - free survival were similar between the two groups .There was some difference in progression - free survival favoring gefitinib in mutation positive patients ( 8.5 versus 6.7 months ; HR 0.613 , 95 % CI 0.308 - 1.221 , . )", "label": "", "metadata": {}, "score": "55.63822"}
{"text": "Toxicity and Adverse Events .The most commonly encountered adverse events ( seen in more than 50 % of the patients in either treatment group ) are listed in Table 2 .", "label": "", "metadata": {}, "score": "55.63966"}
{"text": "In the event of grade 2 or greater plantar - palmar toxicity , fluorouracil should be stopped until recovery .The fluorouracil dosage should be reduced by 20 % .", "label": "", "metadata": {}, "score": "55.7092"}
{"text": "One percent of XTANDI patients compared to 0.3 % on placebo died from infections or sepsis .Falls or injuries related to falls occurred in 4.6 % of XTANDI patients vs 1.3 % on placebo .", "label": "", "metadata": {}, "score": "55.733955"}
{"text": "1394 - 1400 , 2009 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . F. Cappuzzo , C. Ligorio , P. A. J\u00e4nne et al . , \" Prospective study of gefitinib in epidermal growth factor receptor fluorescence in situ hybridization - positive / phospho - akt - positive or never smoker patients with advanced non - small - cell lung cancer : the ONCOBELL trial , \" Journal of Clinical Oncology , vol .", "label": "", "metadata": {}, "score": "55.751854"}
{"text": "Phase III Clinical Studies in Adjuvant and Locally Advanced Setting .A single phase 3 trial of adjuvant gefitinib has been conducted to date ( the BR.19 trial ) , starting in the early 2000s , when a great enthusiasm existed for exploring the potential of this drug in NSCLC treatment [ 38 ] .", "label": "", "metadata": {}, "score": "55.810604"}
{"text": "Table 11 summarizes the safety data obtained from patients that received induction chemotherapy with Taxotere 75 mg / m 2 in combination with cisplatin and fluorouracil followed by radiotherapy ( TAX323 ; 174 patients ) or chemoradiotherapy ( TAX324 ; 251 patients ) .", "label": "", "metadata": {}, "score": "55.914665"}
{"text": "15 , supplement , 2010 , ( abstract no .7508 ) .View at Google Scholar .S. Morita , I. Okamoto , K. Kobayashi et al . , \" Combined survival analysis of prospective clinical trials of gefitinib for non - small cell lung cancer with EGFR mutations , \" Clinical Cancer Research , vol .", "label": "", "metadata": {}, "score": "55.944054"}
{"text": "As with single - agent docetaxel , the primary toxicity in each series was myelosuppression .Gemcitabine has shown significant activity in a wide variety of solid tumors , including cancers of pancreas [ 15 ] , breast [ 16 ] , lung [ 17 ] , and ovary [ 18 ] .", "label": "", "metadata": {}, "score": "56.012054"}
{"text": "The results of this study indicated that the mean dose - normalized AUC of docetaxel was increased 2.2-fold and its clearance was reduced by 49 % when docetaxel was co - administration with ketoconazole [ see Dosage and Administration ( 2.7 ) and Drug - Drug Interactions ( 7 ) ] .", "label": "", "metadata": {}, "score": "56.02711"}
{"text": "The paclitaxel dose was permanently reduced in increments of 10 mg / m 2 for a maximum of two dose reductions for Grade 4 hematologic toxicity or Grade 3 paclitaxel - related non - hematologic toxicity .", "label": "", "metadata": {}, "score": "56.0645"}
{"text": "63 - 68 , 2006 .View at Google Scholar \u00b7 View at Scopus .S. Niho , K. Kubota , K. Goto et al . , \" First - line single agent treatment with gefitinib in patients with advanced non - small - cell lung cancer : a phase II study , \" Journal of Clinical Oncology , vol .", "label": "", "metadata": {}, "score": "56.0677"}
{"text": "These observations led us to study the efficacy and safety of docetaxel / cyclophosphamide combination therapy .Objectives .The primary objectives of this phase I study were as follows : .", "label": "", "metadata": {}, "score": "56.07531"}
{"text": "The primary endpoint , disease - free survival , included local and distant recurrences , contralateral breast cancer and deaths from any cause .The overall reduction in risk of relapse was 25.7 % for TAC - treated patients .", "label": "", "metadata": {}, "score": "56.114143"}
{"text": "12 , pp .1807 - 1813 , 2006 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . D. H. Lee , J. Y. Han , H. G. Lee et al . , \" Gefitinib as a first - line therapy of advanced or metastatic adenocarcinoma of the lung in never - smokers , \" Clinical Cancer Research , vol .", "label": "", "metadata": {}, "score": "56.131523"}
{"text": "Docetaxel is metabolized by the cytochrome P450 system , and in particular the CYP3A enzymes [ 36 ] .Drugs like docetaxel and gefitinib , which share the same metabolic pathway , may influence the breakdown of each other in vivo , increasing the drug concentrations .", "label": "", "metadata": {}, "score": "56.147743"}
{"text": "Seizure occurred in 0.9 % of patients on XTANDI and 0 % of the placebo - treated patients .Grade 3 and higher adverse reactions were reported among 47 % of XTANDI - treated patients and 53 % of placebo - treated patients .", "label": "", "metadata": {}, "score": "56.158203"}
{"text": "The most common adverse reactions leading to treatment discontinuation of Cyramza were proteinuria ( 1.5 % ) and gastrointestinal perforation ( 1.7 % ) .The most common serious adverse events with Cyramza plus FOLFIRI were diarrhea ( 3.6 % ) , intestinal obstruction ( 3.0 % ) , and febrile neutropenia ( 2.8 % ) .", "label": "", "metadata": {}, "score": "56.2791"}
{"text": "Patients must have completed 4 cycles of platinum - based first - line doublet chemotherapy without experiencing disease progression or unacceptable toxicity and are randomized to gefitinib or placebo at 1 : 1 ratio .", "label": "", "metadata": {}, "score": "56.36528"}
{"text": "Patients were also required to have ECOG PS of 0 or 1 .Patients in both arms received paclitaxel 80 mg / m 2 by intravenous infusion on days 1 , 8 , and 15 of each 28-day cycle .", "label": "", "metadata": {}, "score": "56.451687"}
{"text": "Patients whose disease did not progress received radiotherapy ( RT ) according to institutional guidelines ( TPF / RT ) .Patients on the comparator arm received cisplatin ( P ) 100 mg / m 2 on Day 1 , followed by fluorouracil ( F ) 1000 mg / m 2 /day as a continuous infusion on Days 1 - 5 .", "label": "", "metadata": {}, "score": "56.519524"}
{"text": "998 - 1004 , 2006 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . A. Inoue , T. Suzuki , T. Fukuhara et al . , \" Prospective phase II study of gefitinib for chemotherapy - naive patients with advanced non - small - cell lung cancer with epidermal growth factor receptor gene mutations , \" Journal of Clinical Oncology , vol .", "label": "", "metadata": {}, "score": "56.521168"}
{"text": "The IDEAL-2 study included 221 patients who were pretreated with two or more regimens containing platinum and docetaxel [ 16 ] .Overall , the incidence of toxic effects , including skin rash and diarrhea , was lower in patients treated with 250 mg / day as compared with patients treated with 500 mg / day .", "label": "", "metadata": {}, "score": "56.562027"}
{"text": "16 , pp .1659 - 1672 , 2005 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .I. Smith , M. Procter , R. D. Gelber et al . , \" 2-year follow - up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer : a randomised controlled trial , \" The Lancet , vol .", "label": "", "metadata": {}, "score": "56.586395"}
{"text": "Median progression - free survival , which was the primary objective of the study , was 35 weeks for both treatment groups .Nonhematologic Toxicities Safety data were based on 302 patients who were randomized and received treatment .", "label": "", "metadata": {}, "score": "56.60722"}
{"text": "16 , pp .2745 - 2753 , 2008 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .L. V. Sequist , R. G. Martins , D. Spigel et al . , \" First - line gefitinib in patients with advanced non - small - cell lung cancer harboring somatic EGFR mutations , \" Journal of Clinical Oncology , vol .", "label": "", "metadata": {}, "score": "56.623096"}
{"text": "There were no septic deaths in either treatment arm .Gastrointestinal Reactions .In addition to gastrointestinal reactions reflected in the table above , 7 patients in the TAC arm were reported to have colitis / enteritis / large intestine perforation vs. one patient in the FAC arm .", "label": "", "metadata": {}, "score": "56.638626"}
{"text": "Taxotere is contraindicated in patients who have a history of severe hypersensitivity reactions to docetaxel or to other drugs formulated with polysorbate 80 .Severe reactions , including anaphylaxis , have occurred [ see Warnings and Precautions ( 5.4 ) ] .", "label": "", "metadata": {}, "score": "56.6425"}
{"text": "All evaluations were performed according to the RECIST criteria , and all symptoms of toxicity were graded according to the National Cancer Institute common toxicity criteria ( CTC version 2.0 ) .", "label": "", "metadata": {}, "score": "56.700844"}
{"text": "15 , pp .3500 - 3505 , 2001 .View at Google Scholar \u00b7 View at Scopus . H. Edvardsen , P. F. Brunsvig , H. Solvang et al . , \" SNPs in genes coding for ROS metabolism and signalling in association with docetaxel clearance , \" Pharmacogenomics Journal , vol .", "label": "", "metadata": {}, "score": "56.813797"}
{"text": "Sepsis accounted for the majority of the deaths .Non - Small Cell Lung Cancer .Taxotere administered at a dose of 100 mg / m 2 in patients with locally advanced or metastatic non - small cell lung cancer who had a history of prior platinum - based chemotherapy was associated with increased treatment - related mortality ( 14 % and 5 % in two randomized , controlled studies ) .", "label": "", "metadata": {}, "score": "57.001377"}
{"text": "The study used an 80 % power for a 2-sided unstratified long - rank test to detect differences in PFS with hazard ratio of 0.7 .", "label": "", "metadata": {}, "score": "57.034317"}
{"text": "Patients who experience febrile neutropenia should receive G - CSF in all subsequent cycles .Patients who continue to experience this reaction should remain on G - CSF and have their Taxotere dose reduced to 60 mg / m 2 .", "label": "", "metadata": {}, "score": "57.047447"}
{"text": "Docetaxel and Cyclophosphamide in Patients With Advanced Solid Tumors .Docetaxel and Cyclophosphamide in Patients With Advanced Solid Tumors .ABSTRACT :This trial was designed to determine the recommended maximum tolerated dose ( MTD ) , toxicity , pharmacokinetics , and efficacy of docetaxel ( Taxotere ) and cyclophosphamide ( Cytoxan , Neosar ) for phase II studies .", "label": "", "metadata": {}, "score": "57.123055"}
{"text": "-value 0.055 ) and ( 2 ) the association between the SNP rs1341164 in CYP2C8 ( Cytochrome P4502C8 ) and the WHO score at 8 weeks of treatment ( .", "label": "", "metadata": {}, "score": "57.201256"}
{"text": "A large randomized phase 3 trial ( the EURTAC trial , ClinicalTrial.gov ID NCT00446225 ) testing erlotinib in Western patients harbouring EGFR mutation is addressing the first question .", "label": "", "metadata": {}, "score": "57.20601"}
{"text": "The median progression - free and overall survival were 6.5 and 17.8 months , respectively .This is the first report indicating that EGFR mutation - positive patients with poor PS can benefit from front line gefitinib treatment .", "label": "", "metadata": {}, "score": "57.248043"}
{"text": "[ 4 - 7 ] .After the anthracyclines , the nitrogen mustard - alkylating agent cyclophosphamide is the second - most active agent in metastatic breast cancer .", "label": "", "metadata": {}, "score": "57.290215"}
{"text": "Study 3 was a multinational , randomized , double - blind study conducted in patients with NSCLC with disease progression on or after one platinum - based therapy for locally advanced or metastatic disease .", "label": "", "metadata": {}, "score": "57.297516"}
{"text": "Hypersensitivity Reactions .Severe hypersensitivity reactions have been reported [ see Boxed Warning , Warnings and Precautions ( 5.4 ) ] .Minor events , including flushing , rash with or without pruritus , chest tightness , back pain , dyspnea , drug fever , or chills , have been reported and resolved after discontinuing the infusion and instituting appropriate therapy .", "label": "", "metadata": {}, "score": "57.31604"}
{"text": "View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . U.Gatzemeier , A. Pluzanska , A. Szczesna et al . , \" Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non - small - cell lung cancer : the Tarceva lung cancer investigation trial , \" Journal of Clinical Oncology , vol .", "label": "", "metadata": {}, "score": "57.365993"}
{"text": "Patient Characteristics .To date , 39 patients have been enrolled : 26 with breast cancer , 6 with sarcoma , 3 with colon cancer , and 4 with other solid tumors , including lung and head and neck carcinomas .", "label": "", "metadata": {}, "score": "57.377808"}
{"text": "115 - 121 , 2009 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .G. von Minckwitz , W. Jonat , P. Fasching et al . , \" A multicentre phase II study on gefitinib in taxane- and anthracycline - pretreated metastatic breast cancer , \" Breast Cancer Research and Treatment , vol .", "label": "", "metadata": {}, "score": "57.387665"}
{"text": "The median number of chemotherapy cycles in these studies was 5.6 and 5.2 , respectively , corresponding to 16.8- and 15.5-weeks treatment duration .", "label": "", "metadata": {}, "score": "57.38843"}
{"text": "Patients receiving TCF should be closely monitored during the first and subsequent cycles for febrile neutropenia and neutropenic infection [ see Dosage and Administration ( 2.7 ) , Adverse Reactions ( 6 ) ] .", "label": "", "metadata": {}, "score": "57.402946"}
{"text": "No prior hypersensitivity reaction to taxanes or products containing polysorbate 80 .No other active malignancy except carcinoma in situ of the cervix or basal cell skin cancer .", "label": "", "metadata": {}, "score": "57.44396"}
{"text": "However , the incidence of serious adverse reactions was higher in the elderly patients compared to younger patients .Elderly patients treated with TCF should be closely monitored .", "label": "", "metadata": {}, "score": "57.47449"}
{"text": "The proper characterization of a molecular target that allows the identification of responding versus nonresponding patients to a molecular - targeted agent could have important implications for the design of randomized trials evaluating the efficacy of the drug .", "label": "", "metadata": {}, "score": "57.493652"}
{"text": "The initial superiority of chemotherapy was attributed to the benefit that the EGFR - mutation - negative subgroup received from chemotherapy but not from gefitinib , whereas prolonged progression - free survival in the EGFR - mutation - positive subgroup explained the subsequent improvement favoring gefitinib .", "label": "", "metadata": {}, "score": "57.612495"}
{"text": "A multicenter , open - label , randomized trial ( TAX316 ) evaluated the efficacy and safety of Taxotere for the adjuvant treatment of patients with axillary - node - positive breast cancer and no evidence of distant metastatic disease .", "label": "", "metadata": {}, "score": "57.61724"}
{"text": "The primary endpoint of the study was survival .Patients were initially randomized to Taxotere 100 mg / m 2 or best supportive care , but early toxic deaths at this dose led to a dose reduction to Taxotere 75 mg / m 2 .", "label": "", "metadata": {}, "score": "57.642796"}
{"text": "Patients on the comparator arm received cisplatin ( P ) 100 mg / m 2 as a 30-minute to three - hour intravenous infusion on day 1 followed by the continuous intravenous infusion of fluorouracil ( F ) 1000 mg / m 2 /day from day 1 to day 5 .", "label": "", "metadata": {}, "score": "57.687576"}
{"text": "The relationship between changes in performance status , response to therapy , and treatment - related side effects has not been established .Clinical Trial Experience .", "label": "", "metadata": {}, "score": "57.688347"}
{"text": "Unfortunately , molecular features of the tumors , including EGFR mutations , were not recorded in this study .The detrimental effect of maintenance gefitinib after optimal cytoreduction with chemoradiotherapy in stage III NSCLC reported by the S0023 trial excludes the use of the drug in this setting of disease .", "label": "", "metadata": {}, "score": "57.700546"}
{"text": "Seidman A , Hudis C , Crown JPA , et al : Phase II evaluation of Taxotere ( RP56976 , NSC628503 ) as initial chemotherapy for metastatic breast cancer ( abstract ) .", "label": "", "metadata": {}, "score": "57.76014"}
{"text": "21 , pp .2129 - 2139 , 2004 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . H. Asahina , K. Yamazaki , I. Kinoshita et al . , \" A phase II trial of gefitinib as first - line therapy for advanced non - small cell lung cancer with epidermal growth factor receptor mutations , \" British Journal of Cancer , vol .", "label": "", "metadata": {}, "score": "57.805565"}
{"text": "The clinical end - point toxicity was already defined as a two - category variable ( \u00b1toxic response ) .No bias for the SNPs studied with regards to tissue type genotyped ( blood or tumor ) or treatment administered existed for the SNPs except rs1078985 and rs2230949 , where one of the alleles was less frequent in the tumors suggesting LOH in the locus ( .", "label": "", "metadata": {}, "score": "57.841476"}
{"text": "There are no adequate and well - controlled studies in pregnant women using Taxotere .If Taxotere is used during pregnancy , or if the patient becomes pregnant while receiving this drug , the patient should be apprised of the potential hazard to the fetus .", "label": "", "metadata": {}, "score": "57.87953"}
{"text": "Dr. Seidman pointed out that the capecitabine dose in this study is the established dose and the dose for which efficacy has been demonstrated , but it is not well tolerated by many patients , and therefore dose reductions are often necessary .", "label": "", "metadata": {}, "score": "57.950367"}
{"text": "The time to tumor progression was median 93 and 131 days ( intention - to - treat population ) , in the gefitinib and the placebo - treated group , respectively .", "label": "", "metadata": {}, "score": "58.005558"}
{"text": "Overall survival was the primary end - point .This study also closed prematurely , on the recommendation of an unplanned interim analysis that was prompted by the results of the ISEL trial .", "label": "", "metadata": {}, "score": "58.269665"}
{"text": "In this study , 501 patients , with locally advanced SCCHN , and a WHO performance status of 0 or 1 , were randomized to one of two treatment arms .", "label": "", "metadata": {}, "score": "58.377403"}
{"text": "Patients should receive therapeutic G - CSF as soon as possible after discovery of overdose .Other appropriate symptomatic measures should be taken , as needed .", "label": "", "metadata": {}, "score": "58.41739"}
{"text": "OVERDOSAGE .There is no known antidote for Taxotere overdosage .In case of overdosage , the patient should be kept in a specialized unit where vital functions can be closely monitored .", "label": "", "metadata": {}, "score": "58.44601"}
{"text": "Docetaxel is a CYP3A4 substrate .In vitro studies have shown that the metabolism of docetaxel may be modified by the concomitant administration of compounds that induce , inhibit , or are metabolized by cytochrome P450 3A4 .", "label": "", "metadata": {}, "score": "58.46456"}
{"text": "11 , pp .1599 - 1603 , 2006 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . D. R. Spigel , J. D. Hainsworth , E. R. Burkett et al . , \" Single - agent gefitinib in patients with untreated advanced non - small - cell lung cancer and poor performance status : a minnie pearl cancer research network phase II trial , \" Clinical Lung Cancer , vol .", "label": "", "metadata": {}, "score": "58.498695"}
{"text": "6 , pp .1212 - 1219 , 2000 .View at Google Scholar \u00b7 View at Scopus .J. D. Hainsworth , H. A. Burris III , D. A. Yardley et al . , \" Weekly docetaxel in the treatment of elderly patients with advanced breast cancer : a minnie pearl cancer research network phase II trial , \" Journal of Clinical Oncology , vol .", "label": "", "metadata": {}, "score": "58.512634"}
{"text": "Stomatitis / mucositis grade 4 .First episode : stop fluorouracil only , at all subsequent cycles .Second episode : reduce Taxotere dose by 20 % .", "label": "", "metadata": {}, "score": "58.520515"}
{"text": "Severe neurosensory symptoms ( e.g. paresthesia , dysesthesia , pain ) were observed in 5.5 % ( 53/965 ) of metastatic breast cancer patients , and resulted in treatment discontinuation in 6.1 % .", "label": "", "metadata": {}, "score": "58.578808"}
{"text": "The primary dose limiting toxicity was neutropenia .The recommended dose for Taxotere monotherapy was evaluated in a phase 2 single - arm trial in 178 pediatric patients ( median age 12 years , range 1 - 26 years ) with a variety of recurrent / refractory solid tumors .", "label": "", "metadata": {}, "score": "58.834873"}
{"text": "58 - 65 , 1996 .View at Google Scholar \u00b7 View at Scopus .J. Li , M. O. Karlsson , J. Brahmer et al . , \" CYP3A phenotyping approach to predict systemic exposure to EGFR tyrosine kinase inhibitors , \" Journal of the National Cancer Institute , vol .", "label": "", "metadata": {}, "score": "58.84803"}
{"text": "View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .G. D'Addario , D. Rauch , R. Stupp et al . , \" Multicenter phase II trial of gefitinib first - line therapy followed by chemotherapy in advanced non - small - cell lung cancer ( NSCLC ) : SAKK protocol 19/03 , \" Annals of Oncology , vol .", "label": "", "metadata": {}, "score": "58.865658"}
{"text": "Hematologic responses , febrile reactions and infections , and rates of septic death for different regimens are dose related [ see Adverse Reactions ( 6.1 ) , Clinical Studies ( 14 ) ] .", "label": "", "metadata": {}, "score": "58.869186"}
{"text": "Clinical / Scientific Implications .Taxanes , such as paclitaxel and docetaxel , have emerged in the last 10 years as fundamental drugs in the treatment of breast cancer .", "label": "", "metadata": {}, "score": "58.914494"}
{"text": "Prior treatment with one antracycline - containing regimen and/or endocrine therapy for metastatic breast cancer was allowed .A randomization scheme was prepared by the Biostatistics Group , AstraZeneca , and the patients allocated a randomization code strictly sequentially from the pharmacy when entering the study .", "label": "", "metadata": {}, "score": "58.96679"}
{"text": "Advise pregnant women of the potential risk to a fetus .No animal studies have been specifically conducted to evaluate the effect of ramucirumab on reproduction and fetal development .", "label": "", "metadata": {}, "score": "59.12889"}
{"text": "Impaired wound healing : Advise patients that Cyramza has the potential to impair wound healing .Instruct patients not to undergo surgery without first discussing this potential risk with their health care provider [ see Warnings and Precautions ( 5.6 ) ] .", "label": "", "metadata": {}, "score": "59.138535"}
{"text": "Mucositis was experienced by 20 patients ( 13 % ) in the capecitabine group vs 6 patients ( 4 % ) in the gemcitabine group .", "label": "", "metadata": {}, "score": "59.144432"}
{"text": "Taxotere has been studied in a total of 289 pediatric patients : 239 in 2 trials with monotherapy and 50 in combination treatment with cisplatin and 5-fluoruracil ( TCF ) .", "label": "", "metadata": {}, "score": "59.192913"}
{"text": "Patients unable to restart study medication after this period were taken off the study .Before the start of a new cycle , the patients were required to have adequate health status and laboratory values ( as described in the inclusion and exclusion criteria in Section 2.1 ) .", "label": "", "metadata": {}, "score": "59.248753"}
{"text": "11 , pp .1483 - 1489 , 2006 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .K. Yoshida , Y. Yatabe , J. Y. Park et al . , \" Prospective validation for prediction of gefitinib sensitivity by epidermal growth factor receptor gene mutation in patients with non - small cell lung cancer , \" Journal of Thoracic Oncology , vol .", "label": "", "metadata": {}, "score": "59.25148"}
{"text": "However , chemotherapy in combination with lapatinib ( an erbB-2 tyrosine kinase inhibitor ) has been highly effective in breast cancer [ 20 , 21 ] , but not without associated toxicity .", "label": "", "metadata": {}, "score": "59.294186"}
{"text": "Concurrent illnesses , infections , blood product support , and antimicrobial therapies were monitored .Statistical Methods .This single - institution phase II trial was planned with a Simon two - stage optimal design [ 22 ] .", "label": "", "metadata": {}, "score": "59.312263"}
{"text": "Patients must receive premedication with antiemetics , and appropriate hydration ( prior to and after cisplatin administration ) .Prophylaxis for neutropenic infections should be administered .", "label": "", "metadata": {}, "score": "59.322395"}
{"text": "Patients with severe hepatic impairment have not been studied .[ see Warnings and Precautions ( 5.2 ) and Use in Specific Populations ( 8.6 ) ] .", "label": "", "metadata": {}, "score": "59.464245"}
{"text": "Fall - related injuries were more severe in XTANDI patients and included non - pathologic fractures , joint injuries , and hematomas .Grade 1 or 2 hallucinations occurred in 1.6 % of XTANDI patients and 0.3 % on placebo , with the majority on opioid - containing medications at the time of the event .", "label": "", "metadata": {}, "score": "59.558434"}
{"text": "Trudeau ME , Eisenhauer E , Lofters W , et al : Phase II study of Taxotere as first line chemotherapy for metastatic breast cancer ( MBC ) .", "label": "", "metadata": {}, "score": "59.608967"}
{"text": "However , the number of patients in our study is small , and larger studies with more patients are needed for obtaining reliable conclusions about such a relationship .", "label": "", "metadata": {}, "score": "59.696358"}
{"text": "Title : Improved outcomes in elderly patients with metastatic castration - resistant prostate cancer ( mCRPC ) treated with the androgen receptor inhibitor enzalutamide : results from the Phase 3 AFFIRM trial ( Abstract # 16 ) .", "label": "", "metadata": {}, "score": "59.70179"}
{"text": "2253 - 2260 , 2009 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .T. J. Lynch , D. W. Bell , R. Sordella et al . , \" Activating mutations in the epidermal growth factor receptor underlying responsiveness of non - small - cell lung cancer to gefitinib , \" The New England Journal of Medicine , vol .", "label": "", "metadata": {}, "score": "59.71456"}
{"text": "P. Therasse , S. G. Arbuck , E. A. Eisenhauer et al . , \" New guidelines to evaluate the response to treatment in solid tumors , \" Journal of the National Cancer Institute , vol .", "label": "", "metadata": {}, "score": "59.752827"}
{"text": "All patients should be premedicated with an oral corticosteroid prior to the initiation of the infusion of Taxotere [ see Dosage and Administration ( 2.6 ) ] .", "label": "", "metadata": {}, "score": "59.820602"}
{"text": "4493 - 4498 , 2009 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .C. P. Belani , \" The role of irreversible EGFR inhibitors in the treatment of non - small cell lung cancer : overcoming resistance to reversible EGFR inhibitors , \" Cancer Investigation , vol .", "label": "", "metadata": {}, "score": "59.82351"}
{"text": "The dose modifications for cisplatin and fluorouracil in the gastric cancer study are provided below : .Cisplatin dose modifications and delays .Peripheral neuropathy : A neurological examination should be performed before entry into the study , and then at least every 2 cycles and at the end of treatment .", "label": "", "metadata": {}, "score": "59.866966"}
{"text": "No animal studies have been conducted to evaluate the effect of ramucirumab on reproduction and fetal development .The background risk of major birth defects and miscarriage for the indicated populations are unknown .", "label": "", "metadata": {}, "score": "59.962395"}
{"text": "The following adverse reactions have been identified from clinical trials and/or post - marketing surveillance .Because they are reported from a population of unknown size , precise estimates of frequency can not be made .", "label": "", "metadata": {}, "score": "60.15417"}
{"text": "Incidence varies depending on the indication .Adverse reactions are described according to indication .Because clinical trials are conducted under widely varying conditions , adverse reaction rates observed in the clinical trials of a drug can not be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice .", "label": "", "metadata": {}, "score": "60.206177"}
{"text": "View at Google Scholar \u00b7 View at Scopus . H. Swaisland , A. Laight , L. Stafford et al . , \" Pharmacokinetics and tolerability of the orally active selective epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in healthy volunteers , \" Clinical Pharmacokinetics , vol .", "label": "", "metadata": {}, "score": "60.282207"}
{"text": "Taxotere in combination with cisplatin and fluorouracil in gastric cancer or head and neck cancer .Patients treated with Taxotere in combination with cisplatin and fluorouracil must receive antiemetics and appropriate hydration according to current institutional guidelines .", "label": "", "metadata": {}, "score": "60.31703"}
{"text": "Although taxanes are effective drugs , new targeted therapies to further improve survival and prevent progression in patients with metastatic breast cancer are needed .VEGF inhibitors such as BV have been shown to improve outcomes in various tumor types in combination with standard chemotherapy .", "label": "", "metadata": {}, "score": "60.351074"}
{"text": "To be eligible , patients had to have a histologically confirmed advanced solid malignancy ( any type ) and measurable or evaluable disease .Other criteria included a life expectancy 3 months or more and Karnofsky performance status 60 % or more , no prior chemotherapy or radiation within the previous 4 weeks , and normal or only mildly impaired liver function .", "label": "", "metadata": {}, "score": "60.36874"}
{"text": "Docetaxel has the following structural formula : .CLINICAL PHARMACOLOGY .Mechanism of Action .Docetaxel is an antineoplastic agent that acts by disrupting the microtubular network in cells that is essential for mitotic and interphase cellular functions .", "label": "", "metadata": {}, "score": "60.37173"}
{"text": "A Multicenter , Randomized Phase II Study of Two Schedules of Taxotere ( Weekly Versus Every 3 Weeks ) in Elderly or Poor Performance ( ECOG PS 2 ) , Chemotherapy - Naive Patients With Advanced Non - Small Cell Lung Cancer .", "label": "", "metadata": {}, "score": "60.494934"}
{"text": "We wished to distinguish these regions of the true , unknown response rate : at most 0.25 versus at least 0.45 .The 2-stage design called for a maximum of 41 response - evaluable ( r - e ) patients , 17 in stage 1 and 24 in stage 2 .", "label": "", "metadata": {}, "score": "60.548546"}
{"text": "Stomatitis / mucositis grade 3 .First episode : reduce fluorouracil dose by 20 % .Second episode : stop fluorouracil only , at all subsequent cycles .", "label": "", "metadata": {}, "score": "60.572376"}
{"text": "These SNPs were associated with the clearance of docetaxel in these patients and were found in genes related to the metabolism of or response to reactive oxygen species .", "label": "", "metadata": {}, "score": "60.601677"}
{"text": "To assess the collective impact of multiple SNPs on the clinical end - points we performed a leave - one - out cross - validation analysis [ 28 ] .", "label": "", "metadata": {}, "score": "60.632637"}
{"text": "Toxicity - evaluable patients were those who received chemotherapy or any portion of a cycle of therapy .Patients were taken off the study if they had documented PD , an unacceptable adverse event , patient decision to withdraw from the study , investigator judgment to stop treatment , or upon completion of 4 cycles after first documented CR .", "label": "", "metadata": {}, "score": "60.742966"}
{"text": "Monotherapy with Taxotere for NSCLC Previously Treated with Platinum - Based Chemotherapy .Two randomized , controlled trials established that a Taxotere dose of 75 mg / m 2 was tolerable and yielded a favorable outcome in patients previously treated with platinum - based chemotherapy ( see below ) .", "label": "", "metadata": {}, "score": "60.78196"}
{"text": "4 , pp .739 - 745 , 2008 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .M. Z. Wang , L. Y. Li , S. L. Wang , et al . , \" Efficacy and safety of gefitinib as monotherapy for Chinese patients with advanced non - small cell lung cancer , \" Chinese Medical Journal , vol .", "label": "", "metadata": {}, "score": "60.806553"}
{"text": "Ramucirumab exposure at the lowest weekly dose tested in the cynomolgus monkey was 0.2 times the exposure in humans at the recommended dose of ramucirumab as a single agent .", "label": "", "metadata": {}, "score": "60.8724"}
{"text": "4 , pp .303 - 309 , 2004 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . E. S. Casper , M. R. Green , D. P. Kelsen et al . , \" Phase II trial of gemcitabine ( 2 , .", "label": "", "metadata": {}, "score": "60.913185"}
{"text": "Dexamethasone : Docetaxel total body clearance was not modified by pretreatment with dexamethasone .Cisplatin : Clearance of docetaxel in combination therapy with cisplatin was similar to that previously observed following monotherapy with docetaxel .", "label": "", "metadata": {}, "score": "60.980507"}
{"text": "In general , dose selection for an elderly patient should be cautious , reflecting the greater frequency of decreased hepatic , renal , or cardiac function and of concomitant disease or other drug therapy in elderly patients .", "label": "", "metadata": {}, "score": "61.004646"}
{"text": "15 , pp .2442 - 2449 , 2008 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . A. Sutani , Y. Nagai , K. Udagawa et al . , \" Gefitinib for non - small - cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid - locked nucleic acid PCR clamp , \" British Journal of Cancer , vol .", "label": "", "metadata": {}, "score": "61.0701"}
{"text": "Grade 2 : Reduce cisplatin dose by 20 % .Grade 3 : Discontinue treatment .Ototoxicity : In the case of grade 3 toxicity , discontinue treatment .", "label": "", "metadata": {}, "score": "61.080353"}
{"text": "The safety and effectiveness of Cyramza in pediatric patients have not been established .In animal studies , effects on epiphyseal growth plates were identified .", "label": "", "metadata": {}, "score": "61.129364"}
{"text": "Abstract .Purpose .To explore the safety and efficacy of gemcitabine and docetaxel ( GEMDOC ) in previously treated patients with recurrent or metastatic squamous cell carcinoma of the head and neck ( SCCHN ) .", "label": "", "metadata": {}, "score": "61.299297"}
{"text": "570 - 580 , 2006 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .S. M. Tsai , C. Y. Lin , S. H. Wu et al . , \" Side effects after docetaxel treatment in Taiwanese breast cancer patients with CYP3A4 , CYP3A5 , and ABCB1 gene polymorphisms , \" Clinica Chimica Acta , vol .", "label": "", "metadata": {}, "score": "61.317177"}
{"text": "Adjuvant systemic treatment with chemotherapy has improved the outcome for patients with breast cancer [ 1 ] .However , in patients with metastatic disease , chemotherapy may prolong survival , but the disease almost always remains incurable , and new therapeutic strategies are therefore needed .", "label": "", "metadata": {}, "score": "61.337067"}
{"text": "Hypersensitivity reactions require immediate discontinuation of the Taxotere infusion and administration of appropriate therapy [ see Warnings and Precautions ( 5.4 ) ] .Taxotere must not be given to patients who have a history of severe hypersensitivity reactions to Taxotere or to other drugs formulated with polysorbate 80 [ see Contraindications ( 4 ) ] .", "label": "", "metadata": {}, "score": "61.34398"}
{"text": "Patients developing peripheral edema may be treated with standard measures , e.g . , salt restriction , oral diuretic(s ) .Acute Myeloid Leukemia .Treatment - related acute myeloid leukemia ( AML ) or myelodysplasia has occurred in patients given anthracyclines and/or cyclophosphamide , including use in adjuvant therapy for breast cancer .", "label": "", "metadata": {}, "score": "61.347782"}
{"text": "Gastric Cancer .Among the 221 patients treated with Taxotere in combination with cisplatin and fluorouracil in the gastric cancer study , 54 were 65 years of age or older and 2 patients were older than 75 years .", "label": "", "metadata": {}, "score": "61.375694"}
{"text": "RATIONALE : Drugs used in chemotherapy , such as docetaxel , use different ways to stop tumor cells from dividing so they stop growing or die .", "label": "", "metadata": {}, "score": "61.41929"}
{"text": "4 , pp .1408 - 1415 , 2005 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . A. DeMichele , R. Aplenc , J. Botbyl et al . , \" Drug - metabolizing enzyme polymorphisms predict clinical outcome in a node - positive breast cancer cohort , \" Journal of Clinical Oncology , vol .", "label": "", "metadata": {}, "score": "61.446938"}
{"text": "Figure 1 : Kaplan - Meier plot of time to progression ( TTP ) in 36 patients treated with biweekly gemcitabine and docetaxel .Median TTP was 2.3 months ( 95 % CI : 1.5 - 3.8 months ) .", "label": "", "metadata": {}, "score": "61.5377"}
{"text": "Patients on the Taxotere arm received Taxotere ( T ) 75 mg / m 2 followed by cisplatin ( P ) 75 mg / m 2 on Day 1 , followed by fluorouracil ( F ) 750 mg / m 2 per day as a continuous infusion on Days 1 - 5 .", "label": "", "metadata": {}, "score": "61.58767"}
{"text": "One of the SNPs could not be genotyped due to failure of the assay design - probably due to large repeat areas in the DNA sequence around the SNP .", "label": "", "metadata": {}, "score": "61.605877"}
{"text": "Acknowledgment .AstraZeneca is acknowledged for the supply of gefitinib , monitoring of the study , and data management .Furthermore , the study was financially supported by a grant from AstraZeneca .", "label": "", "metadata": {}, "score": "61.68356"}
{"text": "Title : Enzalutamide improves health - related quality of life ( HRQoL ) in men with metastatic castration - resistant prostate cancer ( mCRPC ) following docetaxel - based therapy : results from the AFFIRM study ( Abstract # 17 ) .", "label": "", "metadata": {}, "score": "61.80375"}
{"text": "Unresectable stage IIIB or IV disease .No untreated brain or leptomeningeal metastases .Treated patients must be neurologically stable and the adverse effects from prior therapy must be resolved to grade 2 or less after the completion of treatment .", "label": "", "metadata": {}, "score": "61.81766"}
{"text": "As with other taxoids and other chemotherapeutic agents , fatigue and myalgia were common .Fatigue was moderate in many patients and severe in only a few .", "label": "", "metadata": {}, "score": "61.885765"}
{"text": "Reversible Posterior Leukoencephalopathy Syndrome .Confirm the diagnosis of RPLS with MRI and discontinue Cyramza in patients who develop RPLS .Symptoms may resolve or improve within days , although some patients with RPLS can experience ongoing neurologic sequelae or death .", "label": "", "metadata": {}, "score": "61.9291"}
{"text": "Therefore , gefitinib showed a favourable tolerability profile and antitumor activity also in Japanese patients .Moreover , pharmacokinetic analyses from all these studies confirmed the feasibility of the once daily schedule .", "label": "", "metadata": {}, "score": "62.001858"}
{"text": "Use in Pregnancy .Taxotere can cause fetal harm when administered to a pregnant woman .Docetaxel caused embryofetal toxicities including intrauterine mortality when administered to pregnant rats and rabbits during the period of organogenesis .", "label": "", "metadata": {}, "score": "62.094574"}
{"text": "All patients in both treatment arms who did not have progressive disease were to receive 7 weeks of chemoradiotherapy ( CRT ) following induction chemotherapy 3 to 8 weeks after the start of the last cycle .", "label": "", "metadata": {}, "score": "62.134247"}
{"text": "[ see Clinical Studies ( 14.3 ) ] .Renal Impairment .Hepatic Impairment .Clinical deterioration was reported in patients with Child - Pugh B or C cirrhosis who received single - agent Cyramza [ see Warnings and Precautions ( 5.7 ) and Clinical Pharmacology ( 12.3 ) ] .", "label": "", "metadata": {}, "score": "62.17581"}
{"text": "The results must be interpreted with caution , due to the limited number of patients included into the present study , and do not give an answer to the question of the predictive value of such a panel of SNPs .", "label": "", "metadata": {}, "score": "62.363426"}
{"text": "\" Gemcitabine , capecitabine , and docetaxel are all highly active agents in anthracycline - pretreated metastatic breast cancer .We believed that a comparison of gemcitabine and capecitabine , each combined with docetaxel , would provide valuable information for clinicians in choosing an optimal treatment , \" Dr. Chan said .", "label": "", "metadata": {}, "score": "62.44001"}
{"text": "Table 2 : Baseline characteristics and clinical variables for all 36 patients .Treatment Efficacy .Patient accrual continued to stage 2 of the study design based on the acceptable safety profile , but mainly to help define the true response rate , which appeared to be lower than predicted .", "label": "", "metadata": {}, "score": "62.49286"}
{"text": "Carcinogenesis , Mutagenesis , Impairment of Fertility .No animal studies have been performed to test ramucirumab for potential carcinogenicity or genotoxicity .Inhibition of VEGFR2 signaling in animal models was shown to result in changes to hormone levels critical for pregnancy , and , in monkeys , an increased duration of the follicular cycle .", "label": "", "metadata": {}, "score": "62.50914"}
{"text": "In patients with metastatic breast cancer , taxane treatment demonstrates activity but is not curative .Targeted treatment modalities are therefore necessary in order to improve outcomes in this group .", "label": "", "metadata": {}, "score": "62.525394"}
{"text": "G. L. Clayman , S. M. Lippman , G. E. Laramore , and W. K. Hong , \" Head and neck cancer , \" Cancer Medicine , pp .", "label": "", "metadata": {}, "score": "62.56256"}
{"text": "Taxotere monotherapy was evaluated in a dose - finding phase 1 trial in 61 pediatric patients ( median age 12.5 years , range 1 - 22 years ) with a variety of refractory solid tumors .", "label": "", "metadata": {}, "score": "62.591347"}
{"text": "13 , no .11 , pp .2731 - 2736 , 1995 .View at Google Scholar \u00b7 View at Scopus .B. Lund , O. P. Hansen , K. Theilade , M. Hansen , and J. P. Neijt , \" Phase II study of gemcitabine ( . -difluorodeoxycytidine ) in previously treated ovarian cancer patients , \" Journal of the National Cancer Institute , vol .", "label": "", "metadata": {}, "score": "62.6314"}
{"text": "Prostate Cancer .Of the 333 patients treated with Taxotere every three weeks plus prednisone in the prostate cancer study ( TAX327 ) , 209 patients were 65 years of age or greater and 68 patients were older than 75 years .", "label": "", "metadata": {}, "score": "62.678616"}
{"text": "Monitor patients during the infusion for signs and symptoms of IRRs in a setting with available resuscitation equipment .Immediately and permanently discontinue Cyramza for Grade 3 or 4 IRRs [ see Dosage and Administration ( 2.3 ) ] .", "label": "", "metadata": {}, "score": "62.744774"}
{"text": "Lung Cancer .Intervention ICMJE .Drug : docetaxel .Patients receive docetaxel IV over 1 hour on day 1 .Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity .", "label": "", "metadata": {}, "score": "62.750595"}
{"text": "Because of the potential risk for serious adverse reactions in nursing infants from ramucirumab , advise women that breastfeeding is not recommended during treatment with Cyramza .", "label": "", "metadata": {}, "score": "62.762375"}
{"text": "Patients still alive were censored as of the most recent date on which they were known to be alive .Standard Kaplan - Meier estimates of the censored RD , TTF , TTP , and OS distributions were computed .", "label": "", "metadata": {}, "score": "62.79628"}
{"text": "The results of these studies are summarized in Table 3 .Yang and colleagues observed in 43 patients with exon 19 deletions and L858R mutations a response rate of 95 % and 73.9 % and a progression - free survival of 8.9 and 9.1 months , respectively [ 46 ] .", "label": "", "metadata": {}, "score": "62.797867"}
{"text": "Prophylactic G - CSF may be used to mitigate the risk of hematological toxicities [ see Dosage and Administration ( 2.7 ) ] .Non - Small Cell Lung Cancer .", "label": "", "metadata": {}, "score": "62.81311"}
{"text": "Table 1 : Phase II studies of biweekly gemcitabine and docetaxel ( GEMDOC ) .The biweekly GEMDOC combination is an attractive regimen in the treatment of advanced head and neck cancer since both agents are active against SCCHN with a low toxicity profile .", "label": "", "metadata": {}, "score": "62.866367"}
{"text": "To view content sources and attributions , please refer to our editorial policy .Gemcitabine / Docetaxel Comparable to Capecitabine/ Docetaxel in Metastatic Breast Cancer .", "label": "", "metadata": {}, "score": "62.954628"}
{"text": "To assess the combinatorial effect of multiple SNPs , leave - one - out cross - validation ( LOOCV ) analysis implemented in Bioclassifier [ 28 ] was utilized .", "label": "", "metadata": {}, "score": "62.957973"}
{"text": "In patients with normal LFTs at baseline , bilirubin values greater than the ULN occurred in 8.9 % of patients .Whether these changes were related to the drug or underlying disease has not been established .", "label": "", "metadata": {}, "score": "62.959995"}
{"text": "Overall survival results are presented in Table 21 and Figure 10 .REFERENCES .NIOSH Alert : Preventing occupational exposures to antineoplastic and other hazardous drugs in healthcare settings .", "label": "", "metadata": {}, "score": "63.027878"}
{"text": "View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .L. Specht , S. K. Larsen , and H. S. Hansen , \" Phase II study of docetaxel and cisplatin in patients with recurrent or disseminated squamous - cell carcinoma of the head and neck , \" Annals of Oncology , vol .", "label": "", "metadata": {}, "score": "63.06437"}
{"text": "PRIOR CONCURRENT THERAPY : .Biologic therapy .Not specified .Chemotherapy .No prior chemotherapy .Endocrine therapy .Not specified .Radiotherapy .Recovered from prior radiotherapy ( i.e. , side effects resolved to grade 2 or less ) .", "label": "", "metadata": {}, "score": "63.075405"}
{"text": "View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . F. R. Hirsch , M. Varella - Garcia , P. A. Bunn Jr. et al . , \" Molecular predictors of outcome with gefitinib in a phase III placebo - controlled study in advanced non - small - cell lung cancer , \" Journal of Clinical Oncology , vol .", "label": "", "metadata": {}, "score": "63.16301"}
{"text": "Other Names : .Taxotere .Docefrez .Study Arm ( s ) .Experimental : Docetaxel .Intervention : Drug : docetaxel .Not Provided .", "label": "", "metadata": {}, "score": "63.22069"}
{"text": "View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . A. Pelegri , L. Calvo , J. Florian et al . , \" Every other week combination of gemcitabine and docetaxel as first line therapy in advanced breast cancer patients : preliminary results from a phase II trial , \" Breast Cancer Research and Treatment , vol .", "label": "", "metadata": {}, "score": "63.24372"}
{"text": "The response rate in these studies was relatively high ( 54 % and 39 % , resp . )However , the absence of a comparator arm makes it difficult to evaluate these response data [ 13 , 14 ] .", "label": "", "metadata": {}, "score": "63.26058"}
{"text": "Patients with a history of severe hypersensitivity reactions should not be rechallenged with Taxotere .Hypersensitivity reactions may occur within a few minutes following initiation of a Taxotere infusion .", "label": "", "metadata": {}, "score": "63.2801"}
{"text": "Median time on treatment was 4.8 months in both arms .Differences were not significant for both overall survival ( HR 1.24 ; 95 % CI 0.94 - 1.64 ; . ) , with a negative trend for gefitinib treatment .", "label": "", "metadata": {}, "score": "63.29296"}
{"text": "Toxic Deaths .Breast Cancer .Among patients dosed at 60 mg / m 2 , mortality related to treatment occurred in 0.6 % ( 3/481 ) of patients with normal liver function , and in 3 of 7 patients with abnormal liver function .", "label": "", "metadata": {}, "score": "63.4024"}
{"text": "Following chemotherapy , patients should receive chemoradiotherapy [ see Dosage and Administration ( 2.7 ) ] .Premedication Regimen .For hormone - refractory metastatic prostate cancer , given the concurrent use of prednisone , the recommended premedication regimen is oral dexamethasone 8 mg , at 12 hours , 3 hours and 1 hour before the Taxotere infusion [ see Warnings and Precautions ( 5.4 ) ] .", "label": "", "metadata": {}, "score": "63.432957"}
{"text": "Each administration of Taxotere Injection at 100 mg / m 2 delivers 2.0 g / m 2 of ethanol .For a patient with a BSA of 2.0 m 2 , this would deliver 4.0 grams of ethanol [ see Description ( 11 ) ] .", "label": "", "metadata": {}, "score": "63.587734"}
{"text": "Cardiovascular Reactions .Hypotension occurred in 2.8 % of patients with solid tumors ; 1.2 % required treatment .Clinically meaningful events such as heart failure , sinus tachycardia , atrial flutter , dysrhythmia , unstable angina , pulmonary edema , and hypertension occurred rarely .", "label": "", "metadata": {}, "score": "63.605423"}
{"text": "\" The dose of capecitabine in this international trial is 2,000 mg / m 2 in divided doses on 14 of the 21 days in the cycle .", "label": "", "metadata": {}, "score": "63.72238"}
{"text": "Six Abstracts Presented Include Data from Phase II Study Investigating XTANDI(R ) ( enzalutamide ) Capsules in Hormone - Naive Prostate Cancer .SAN FRANCISCO , CA and .", "label": "", "metadata": {}, "score": "63.734165"}
{"text": "Higher doses facilitated by growth factor may be more feasible in the adjuvant setting , in previously untreated or minimally treated patients .This merits further investigation .", "label": "", "metadata": {}, "score": "63.766228"}
{"text": "Cardiovascular Reactions .One patient in each arm died due to heart failure .Acute Myeloid Leukemia ( AML ) .Treatment - related acute myeloid leukemia or myelodysplasia is known to occur in patients treated with anthracyclines and/or cyclophosphamide , including use in adjuvant therapy for breast cancer .", "label": "", "metadata": {}, "score": "63.77278"}
{"text": "For chemotherapy - na\u00efve patients , Taxotere was evaluated in combination with cisplatin .The recommended dose of Taxotere is 75 mg / m 2 administered intravenously over 1 hour immediately followed by cisplatin 75 mg / m 2 over 30 - 60 minutes every 3 weeks [ see Dosage and Administration ( 2.7 ) ] .", "label": "", "metadata": {}, "score": "63.786938"}
{"text": "Statistical Analysis - SNP Studies .The association between individual SNPs and the clinical endpoints was analysed using standard chi - square tests included in SPSS v15.0 .", "label": "", "metadata": {}, "score": "63.93638"}
{"text": "When given in combination , administer Cyramza prior to administration of paclitaxel .Non - Small Cell Lung Cancer .The recommended dose of Cyramza is 10 mg / kg administered by intravenous infusion over 60 minutes on day 1 of a 21-day cycle prior to docetaxel infusion .", "label": "", "metadata": {}, "score": "64.00586"}
{"text": "Cyramza has not been studied in patients with serious or non - healing wounds .Cyramza , an antiangiogenic therapy , has the potential to adversely affect wound healing .", "label": "", "metadata": {}, "score": "64.40779"}
{"text": "Patients are followed at 1 month and then every 2 - 3 months thereafter .PROJECTED ACCRUAL : A total of 210 - 230 patients ( 105 - 115 per treatment arm ) will be accrued for this study .", "label": "", "metadata": {}, "score": "64.49123"}
{"text": "Alternative non - taxane cancer treatment should be considered .Asthenia .Severe asthenia has been reported in 14.9 % ( 144/965 ) of metastatic breast cancer patients but has led to treatment discontinuation in only 1.8 % .", "label": "", "metadata": {}, "score": "64.51005"}
{"text": "In other models , VEGFR2 signaling was associated with development and maintenance of endometrial and placental vascular function , successful blastocyst implantation , maternal and feto - placental vascular differentiation , and development during early pregnancy in rodents and non - human primates .", "label": "", "metadata": {}, "score": "64.69269"}
{"text": "16 ( 55 % ) experienced clinical benefit ( response or stable disease ) .Six ( 21 % ) patients achieved partial response ( PR ) , none achieved complete response ( CR ) , and the overall response rate ( ORR ) was 21 % ( 95 % CI : 0.10 - 0.38 ) .", "label": "", "metadata": {}, "score": "64.735794"}
{"text": "Interventional .Study Phase .Phase 2 .Study Design ICMJE .Endpoint Classification : Efficacy Study Intervention Model : Single Group Assignment Masking : Open Label Primary Purpose : Treatment .", "label": "", "metadata": {}, "score": "64.77971"}
{"text": "160 - 165 , 2009 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus Cyramza .WARNING : HEMORRHAGE , GASTROINTESTINAL PERFORATION , AND IMPAIRED WOUND HEALING .", "label": "", "metadata": {}, "score": "64.78571"}
{"text": "Docetaxel 's pharmacokinetic profile is consistent with a three - compartment pharmacokinetic model , with half - lives for the \u03b1 , \u03b2 , and \u03b3 phases of 4 min , 36 min , and 11.1 hr , respectively .", "label": "", "metadata": {}, "score": "64.82933"}
{"text": "Taxotere was studied in combination with cisplatin and 5-fluorouracil ( TCF ) versus cisplatin and 5-fluorouracil ( CF ) for the induction treatment of nasopharyngeal carcinoma ( NPC ) in pediatric patients prior to chemoradiation consolidation .", "label": "", "metadata": {}, "score": "65.00371"}
{"text": "This Patient Information leaflet summarizes the most important information about Taxotere .If you would like more information , talk with your doctor .You can ask your pharmacist or doctor for information about Taxotere that is written for health professionals .", "label": "", "metadata": {}, "score": "65.10296"}
{"text": "Report the qualitative and quantitative toxicity of the two drugs in combination , administered intravenously over 1 hour every 21 days , as well as the reversibility of toxicity .", "label": "", "metadata": {}, "score": "65.17669"}
{"text": "The discontinuation rate due to skin toxicity was 1.6 % ( 15/965 ) for metastatic breast cancer patients .Among 92 breast cancer patients premedicated with 3-day corticosteroids , there were no cases of severe skin toxicity reported and no patient discontinued Taxotere due to skin toxicity .", "label": "", "metadata": {}, "score": "65.24156"}
{"text": "Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA - approved therapy for these aberrations prior to receiving Cyramza .Colorectal Cancer .", "label": "", "metadata": {}, "score": "65.33664"}
{"text": "In addition , physical and chemical in - use stability of the infusion solution prepared as recommended has been demonstrated in non - PVC bags up to 48 hours when stored between 2 \u00b0 C and 8 \u00b0 C ( 36 and 46 \u00b0 F ) .", "label": "", "metadata": {}, "score": "65.375755"}
{"text": "BV has been shown to improve OS and PFS in these previous studies .The E2100 trial , a phase III trial of weekly paclitaxel versus weekly paclitaxel / bevacizumab for metastatic breast cancer , by K. Miller , et al .", "label": "", "metadata": {}, "score": "65.42583"}
{"text": "Medivation , Inc. ( NASDAQ : MDVN ) and Astellas Pharma Inc. ( .Tokyo : 4503 ) announced that data for enzalutamide , an oral androgen receptor inhibitor , will be presented at the .", "label": "", "metadata": {}, "score": "65.43541"}
{"text": "Our panel of SNPs correctly classified the response in these two groups in 83.3 % of the samples ( ., Table 4 ) .More close analysis at the LOOCV ( leave one out cross validation analysis ) result points to the rs2228001 in XPC ( xeroderma pigmentosum complementation group C ) gene contributing mostly to this predictive potential .", "label": "", "metadata": {}, "score": "65.44208"}
{"text": "The median progression - free survival and overall survival did not differ significantly between patients with exon 19 deletion and those with L858R point mutation ( 11.5 months versus 10.8 months , resp . )", "label": "", "metadata": {}, "score": "65.52283"}
{"text": "The safety and efficacy of Taxotere in the induction treatment of patients with locally advanced ( unresectable , low surgical cure , or organ preservation )", "label": "", "metadata": {}, "score": "65.59596"}
{"text": "Administration Precautions .Taxotere is a cytotoxic anticancer drug and , as with other potentially toxic compounds , caution should be exercised when handling and preparing Taxotere solutions .", "label": "", "metadata": {}, "score": "65.69667"}
{"text": "Advise females of reproductive potential to use effective contraception during treatment with Cyramza and for at 3 least months after the last dose of Cyramza [ see Use in Specific Populations ( 8.1 , 8.3 ) ] .", "label": "", "metadata": {}, "score": "65.81323"}
{"text": "American Society of Health - System Pharmacists .( 2006 ) ASHP Guidelines on Handling Hazardous Drugs .Am J Health - Syst Pharm .Polovich , M. , White , J. M. , & Kelleher , L.O. ( eds . )", "label": "", "metadata": {}, "score": "65.84461"}
{"text": "Cyramza \u00ae as a single agent , or in combination with paclitaxel , is indicated for the treatment of patients with advanced or metastatic , gastric or gastro - esophageal junction adenocarcinoma with disease progression on or after prior fluoropyrimidine- or platinum - containing chemotherapy .", "label": "", "metadata": {}, "score": "65.85012"}
{"text": "For cisplatin dosage adjustments , see manufacturers ' prescribing information .Combination therapy with Taxotere for hormone - refractory metastatic prostate cancer .If the patient continues to experience these reactions at 60 mg / m 2 , the treatment should be discontinued .", "label": "", "metadata": {}, "score": "66.00661"}
{"text": "226 - 236 , 2008 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .J. Gu , H. Zhao , C. P. Dinney et al . , \" Nucleotide excision repair gene polymorphisms and recurrence after treatment for superficial bladder cancer , \" Clinical Cancer Research , vol .", "label": "", "metadata": {}, "score": "66.06614"}
{"text": "Tumor evaluation was performed after each seven - week cycle , and the patients continued on study medication until disease progression or the appearance of unacceptable toxicity .", "label": "", "metadata": {}, "score": "66.1412"}
{"text": "Patients in whom alcohol should be avoided or minimized should consider the alcohol content of Taxotere Injection .Alcohol could impair their ability to drive or use machines immediately after infusion .", "label": "", "metadata": {}, "score": "66.25061"}
{"text": "Induction chemotherapy followed by radiotherapy ( TAX323 ) .The safety and efficacy of Taxotere in the induction treatment of patients with squamous cell carcinoma of the head and neck ( SCCHN ) was evaluated in a multicenter , open - label , randomized trial ( TAX323 ) .", "label": "", "metadata": {}, "score": "66.294426"}
{"text": "Assuming the hypothesis is true , the goal of the trial is to have a probability of 0.90 of satisfying both criteria .This study design will require 66 patients ( 33 per arm ) [ 25 ] .", "label": "", "metadata": {}, "score": "66.39418"}
{"text": "207 - 217 , 2006 .View at Google Scholar . A. Tsalenko , A. Ben - Dor , N. Cox , and Z. Yakhini , \" Methods for analysis and visualization of SNP genotype data for complex diseases , \" Pacific Symposium on Biocomputing , pp .", "label": "", "metadata": {}, "score": "66.47144"}
{"text": "11 , pp .783 - 792 , 2001 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .M. F. Rimawi , P. B. Shetty , H. L. Weiss et al . , \" Epidermal growth factor receptor expression in breast cancer association with biologic phenotype and clinical outcomes , \" Cancer , vol .", "label": "", "metadata": {}, "score": "66.49838"}
{"text": "Development of Gefitinib in \" Selected \" Patients .Phase II Clinical Studies .The recent discovery that some somatic mutations in the tyrosine kinase domain of the EGFR gene are associated with a high response to EGFR tyrosine kinase inhibitors in NSCLC highlighted the need for patient selection through molecular screening [ 42 , 43 ] .", "label": "", "metadata": {}, "score": "66.51099"}
{"text": "The safety profile is generally similar in patients receiving Taxotere for the treatment of breast cancer and in patients with other tumor types ( See Table 3 ) .", "label": "", "metadata": {}, "score": "66.5622"}
{"text": "Table 8 presents safety data from two arms of an open label , randomized controlled trial ( TAX326 ) that enrolled patients with unresectable stage IIIB or IV non - small cell lung cancer and no history of prior chemotherapy .", "label": "", "metadata": {}, "score": "66.69838"}
{"text": "Results .Between March 2006 and April 2007 , 736 patients at 104 sites in 24 countries were randomized .The median follow up was 10.2 months ( range 0 - 17.5 months ) .", "label": "", "metadata": {}, "score": "66.71033"}
{"text": "These reactions were described using NCI Common Toxicity Criteria regardless of relationship to study treatment , except for the hematologic toxicities or where otherwise noted .", "label": "", "metadata": {}, "score": "66.83327"}
{"text": "The SNPs were originally part of a panel of 1030 SNPs genotyped in 193 cancer patients , including the NSCLC patients .The biological justification for our SNP selection in the original panel is thoroughly described in [ 27 ] but can in brief be described as SNPs in genes of relevance for the metabolism of reactive oxygen species ( ROS ) or the response to ROS .", "label": "", "metadata": {}, "score": "66.862274"}
{"text": "Elimination : A study of 14 C - docetaxel was conducted in three cancer patients .Docetaxel was eliminated in both the urine and feces following oxidative metabolism of the tert -butyl ester group , but fecal excretion was the main elimination route .", "label": "", "metadata": {}, "score": "66.91271"}
{"text": "Results .Patient Demographics and Disposition .Thirty - six patients were enrolled between May 2005 and May 2008 .Median age was 60 years ( range : 46 to 79 years ) ( Table 2 ) .", "label": "", "metadata": {}, "score": "66.931244"}
{"text": "6 , pp .513 - 523 , 2010 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . H. Edvardsen , G. Irene Grenaker Alnaes , A. Tsalenko , et al . , \" Experimental validation of data mined single nucleotide polymorphisms from several databases and consecutive dbSNP builds , \" Pharmacogenetics and Genomics , vol .", "label": "", "metadata": {}, "score": "66.964355"}
{"text": "Clinical Studies .Gastric Cancer .The major efficacy outcome measure was overall survival and the supportive efficacy outcome measure was progression - free survival .", "label": "", "metadata": {}, "score": "66.97586"}
{"text": "More than 30 days since prior anticancer investigational drugs .Concurrent supportive care investigational agents allowed .Gender .Both .Ages .18 Years and older .", "label": "", "metadata": {}, "score": "67.03222"}
{"text": "XTANDI decreased proliferation and induced cell death of prostate cancer cells in vitro , and decreased tumor volume in a mouse prostate cancer xenograft model .", "label": "", "metadata": {}, "score": "67.262405"}
{"text": "Non - Small Cell Lung Cancer .Taxotere as a single agent is indicated for the treatment of patients with locally advanced or metastatic non - small cell lung cancer after failure of prior platinum - based chemotherapy .", "label": "", "metadata": {}, "score": "67.2666"}
{"text": "Animal Toxicology and/or Pharmacology .Adverse effects in the kidney ( glomerulonephritis ) occurred in monkeys at doses of 16 - 50 mg / kg ( 0.7 - 5.5 times the exposure in humans at the recommended dose of ramucirumab as a single agent ) .", "label": "", "metadata": {}, "score": "67.29344"}
{"text": "Breast Cancer .If the patient continues to experience these reactions , the dosage should either be decreased from 75 mg / m 2 to 55 mg / m 2 or the treatment should be discontinued .", "label": "", "metadata": {}, "score": "67.42053"}
{"text": "View at Google Scholar \u00b7 View at Scopus . A. H. Klopp , A. Jhingran , L. Ramdas et al . , \" Gene expression changes in cervical squamous cell carcinoma after initiation of chemoradiation and correlation with clinical outcome , \" International Journal of Radiation Oncology Biology Physics , vol .", "label": "", "metadata": {}, "score": "67.42126"}
{"text": "Gastric Adenocarcinoma .A multicenter , open - label , randomized trial was conducted to evaluate the safety and efficacy of Taxotere for the treatment of patients with advanced gastric adenocarcinoma , including adenocarcinoma of the gastroesophageal junction , who had not received prior chemotherapy for advanced disease .", "label": "", "metadata": {}, "score": "67.57663"}
{"text": "Taxotere was administered as a 1-hour infusion ; all other drugs were given as intravenous bolus on day 1 .In both arms , after the last cycle of chemotherapy , patients with positive estrogen and/or progesterone receptors received tamoxifen 20 mg daily for up to 5 years .", "label": "", "metadata": {}, "score": "67.58757"}
{"text": "Arterial thromboembolic events : Advise patients of an increased risk of an arterial thromboembolic event [ see Warnings and Precautions ( 5.2 ) ] .Hypertension : Advise patients to undergo routine blood pressure monitoring and to contact their health care provider if blood pressure is elevated or if symptoms from hypertension occur including severe headache , lightheadedness , or neurologic symptoms [ see Warnings and Precautions ( 5.3 ) ] .", "label": "", "metadata": {}, "score": "67.69261"}
{"text": "- administration of XTANDI with strong or moderate CYP3A4 and CYP2C8 inducers can alter the plasma exposure of XTANDI and should be avoided if possible .", "label": "", "metadata": {}, "score": "67.82247"}
{"text": "Symptoms of IRRs included rigors / tremors , back pain / spasms , chest pain and/or tightness , chills , flushing , dyspnea , wheezing , hypoxia , and paresthesia .", "label": "", "metadata": {}, "score": "67.89227"}
{"text": "This regimen is administered every 3 weeks for 4 cycles .Following chemotherapy , patients should receive radiotherapy .[ see Dosage and Administration ( 2.7 ) ] .", "label": "", "metadata": {}, "score": "67.95335"}
{"text": "Your body may hold too much fluid ( severe fluid retention ) during treatment with Taxotere .This can be life threatening .To decrease the chance of this happening , you must take another medicine , a corticosteroid , before each Taxotere treatment .", "label": "", "metadata": {}, "score": "67.98804"}
{"text": "M. A. Olayioye , R. M. Neve , H. A. Lane , and N. E. Hynes , \" The ErbB signaling network : receptor heterodimerization in development and cancer , \" The EMBO Journal , vol .", "label": "", "metadata": {}, "score": "68.0839"}
{"text": "USE IN SPECIFIC POPULATIONS .Pregnancy .Based on its mechanism of action and findings in animals , Taxotere can cause fetal harm when administered to a pregnant woman .", "label": "", "metadata": {}, "score": "68.15849"}
{"text": "Disseminated intravascular coagulation ( DIC ) , often in association with sepsis or multiorgan failure , has been reported .Cases of acute myeloid leukemia and myelodysplasic syndrome have been reported in association with Taxotere when used in combination with other chemotherapy agents and/or radiotherapy .", "label": "", "metadata": {}, "score": "68.245605"}
{"text": "The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay .Additionally , the observed incidence of antibody ( including neutralizing antibody ) positivity in an assay may be influenced by several factors including assay methodology , sample handling , timing of sample collection , concomitant medications , and underlying disease .", "label": "", "metadata": {}, "score": "68.28143"}
{"text": "Proc Am Soc Clin Oncol 14:97 , 1995 .Ravdin P , Valero V , Nabholtz JM , et al : Efficacy of a 5-day corticosteroid premedication in ameliorating Taxotere induced fluid retention ( abstract ) .", "label": "", "metadata": {}, "score": "68.32085"}
{"text": "Women of childbearing potential should be advised to avoid becoming pregnant during therapy with Taxotere .Taxotere can cause fetal harm when administered to a pregnant woman .", "label": "", "metadata": {}, "score": "68.372116"}
{"text": "Permanently discontinue Cyramza in patients who experience severe bleeding [ see Dosage and Administration ( 2.3 ) , Warnings and Precautions ( 5.1 ) ] .", "label": "", "metadata": {}, "score": "68.41182"}
{"text": "Based on its mechanism of action , Cyramza can cause fetal harm [ see Use in Specific Populations ( 8.1 ) ] .Advise females of reproductive potential to use effective contraception while receiving Cyramza and for at least 3 months after the last dose of Cyramza .", "label": "", "metadata": {}, "score": "68.55768"}
{"text": "Monotherapy with Taxotere for locally advanced or metastatic breast cancer after failure of prior chemotherapy .These reactions were described using COSTART terms and were considered possibly or probably related to Taxotere .", "label": "", "metadata": {}, "score": "68.692024"}
{"text": "Ten ( 28 % ) patients had SD .The median RD for the 6 responding patients was 3.2 months ( 80 % CI : 2 - 6.1 ) .", "label": "", "metadata": {}, "score": "68.79564"}
{"text": "Non - Small Cell Lung Cancer .Monotherapy with Taxotere for NSCLC treatment after failure of prior platinum - based chemotherapy .Combination therapy with Taxotere for chemotherapy - na\u00efve NSCLC .", "label": "", "metadata": {}, "score": "68.81746"}
{"text": "In the Taxotere every three week arm , a statistically significant overall survival advantage was demonstrated compared to mitoxantrone .In the Taxotere weekly arm , no overall survival advantage was demonstrated compared to the mitoxantrone control arm .", "label": "", "metadata": {}, "score": "68.93205"}
{"text": "Premedication .Prior to each Cyramza infusion , premedicate all patients with an intravenous histamine H 1 antagonist ( e.g. , diphenhydramine hydrochloride ) .For patients who have experienced a Grade 1 or 2 infusion - related reaction , also premedicate with dexamethasone ( or equivalent ) and acetaminophen prior to each Cyramza infusion [ see Dosage and Administration ( 2.3 ) ] .", "label": "", "metadata": {}, "score": "68.957855"}
{"text": "Lung Cancer .Monotherapy with Taxotere for unresectable , locally advanced or metastatic NSCLC previously treated with platinum - based chemotherapy .Taxotere 75 mg / m 2 : Treatment emergent adverse drug reactions are shown in Table 7 .", "label": "", "metadata": {}, "score": "69.042145"}
{"text": "Prostate Cancer .Gastric Adenocarcinoma .Taxotere in combination with cisplatin and fluorouracil is indicated for the treatment of patients with advanced gastric adenocarcinoma , including adenocarcinoma of the gastroesophageal junction , who have not received prior chemotherapy for advanced disease .", "label": "", "metadata": {}, "score": "69.10122"}
{"text": "For hormone - refractory metastatic prostate cancer , the recommended dose of Taxotere is 75 mg / m 2 every 3 weeks as a 1 hour intravenous infusion .", "label": "", "metadata": {}, "score": "69.13457"}
{"text": "Instruct patients to immediately report signs of a hypersensitivity reaction .Tell patients to watch for signs of fluid retention such as peripheral edema in the lower extremities , weight gain and dyspnea .", "label": "", "metadata": {}, "score": "69.18274"}
{"text": "About 80 % of the radioactivity recovered in feces is excreted during the first 48 hours as 1 major and 3 minor metabolites with very small amounts ( less than 8 % ) of unchanged drug .", "label": "", "metadata": {}, "score": "69.25133"}
{"text": "Discontinue Cyramza therapy in patients with impaired wound healing .Withhold Cyramza prior to surgery and discontinue Cyramza if a patient develops wound healing complications [ see Dosage and Administration ( 2.3 ) , Warnings and Precautions ( 5.6 ) ] .", "label": "", "metadata": {}, "score": "69.256165"}
{"text": "Pregnancy .Based on its mechanism of action [ see Clinical Pharmacology ( 12.1 ) ] , Cyramza can cause fetal harm .Animal models link angiogenesis , VEGF and VEGF Receptor 2 ( VEGFR2 ) to critical aspects of female reproduction , embryofetal development , and postnatal development .", "label": "", "metadata": {}, "score": "69.25708"}
{"text": "Severe fluid retention has been reported following Taxotere therapy .Patients should be premedicated with oral corticosteroids prior to each Taxotere administration to reduce the incidence and severity of fluid retention [ see Dosage and Administration ( 2.6 ) ] .", "label": "", "metadata": {}, "score": "69.26013"}
{"text": "In order to monitor the occurrence of neutropenia , which may be severe and result in infection , frequent blood cell counts should be performed on all patients receiving Taxotere [ see Warnings and Precautions ( 5.3 ) ] .", "label": "", "metadata": {}, "score": "69.37024"}
{"text": "Data were presented at 2010 ASCO Annual Meeting .Median age of patients was 67 ; 54 % were male , 54 % PS 0 and most of them were ever smoker ( 89 % ) ; most of tumors were adenocarcinoma ( 59 % ) ; only 17 % of patients received chemotherapy .", "label": "", "metadata": {}, "score": "69.414024"}
{"text": "Hematologic Effects .Perform frequent peripheral blood cell counts on all patients receiving Taxotere .Frequent monitoring of blood counts is , therefore , essential so that dose can be adjusted .", "label": "", "metadata": {}, "score": "69.474014"}
{"text": "C. Palmieri and A. Jones , \" The 2011 EBCTCG polychemotherapy overview , \" The Lancet , vol .379 , no .9814 , pp .", "label": "", "metadata": {}, "score": "69.49078"}
{"text": "In TAC - treated patients , the risk of delayed myelodysplasia or myeloid leukemia requires hematological follow - up .Cutaneous Reactions .Localized erythema of the extremities with edema followed by desquamation has been observed .", "label": "", "metadata": {}, "score": "69.5004"}
{"text": "Animal models link angiogenesis , VEGF and VEGF Receptor 2 ( VEGFR2 ) to critical aspects of female reproduction , embryofetal development , and postnatal development .", "label": "", "metadata": {}, "score": "69.514656"}
{"text": "However , compared with patients receiving placebo , patients receiving enzalutamide had a significantly prolonged time to HRQoL deterioration .Title : Long - term responders to enzalutamide ( ENZA ) during the phase 3 AFFIRM trial : baseline characteristics and efficacy outcomes ( Abstract # 20 ) .", "label": "", "metadata": {}, "score": "69.52727"}
{"text": "Monitor thyroid function during treatment with Cyramza .In Study 4 , the incidence of hypothyroidism reported as an adverse event was 2.6 % in the Cyramza plus FOLFIRI treated patients and 0.9 % in the placebo plus FOLFIRI treated patients .", "label": "", "metadata": {}, "score": "69.58235"}
{"text": "Presenter : David Miles , MD Presenter 's Affiliation : Mount Vernon Cancer Center , UK Type of Session : Scientific .Background .Bevacizumab ( BV ) is a monoclonal antibody to VEGF that inhibits angiogenenesis , and therefore prevents tumor growth .", "label": "", "metadata": {}, "score": "69.63619"}
{"text": "Taxotere 30 mg / m 2 administered weekly for the first 5 weeks in a 6-week cycle for 5 cycles .Mitoxantrone 12 mg / m 2 every 3 weeks for 10 cycles .", "label": "", "metadata": {}, "score": "69.77027"}
{"text": "Alcohol Content .Cases of intoxication have been reported with some formulations of docetaxel due to the alcohol content .The alcohol content in a dose of Taxotere Injection may affect the central nervous system and should be taken into account for patients in whom alcohol intake should be avoided or minimized .", "label": "", "metadata": {}, "score": "69.780014"}
{"text": "AML occurred in the adjuvant breast cancer trial ( TAX316 ) .The cumulative risk of developing treatment - related AML at 5 years in TAX316 was 0.4 % for TAC - treated patients and 0.1 % for FAC - treated patients .", "label": "", "metadata": {}, "score": "69.865204"}
{"text": "Permanently discontinue Cyramza in patients who experience a gastrointestinal perforation [ see Dosage and Administration ( 2.3 ) , Warnings and Precautions ( 5.5 ) ] .", "label": "", "metadata": {}, "score": "69.91882"}
{"text": "Interstitial lung disease was reported in 6 patients ( 5.3 % ) in the gefitinib arm , with one of these fatal .Ongoing Phase III / IV Studies in NSCLC .", "label": "", "metadata": {}, "score": "70.39734"}
{"text": "Control hypertension prior to initiating treatment with Cyramza .Monitor blood pressure every two weeks or more frequently as indicated during treatment .Temporarily suspend Cyramza for severe hypertension until medically controlled .", "label": "", "metadata": {}, "score": "70.55491"}
{"text": "Cardiovascular : atrial fibrillation , deep vein thrombosis , ECG abnormalities , thrombophlebitis , pulmonary embolism , syncope , tachycardia , myocardial infarction .Cutaneous : very rare cases of cutaneous lupus erythematosus and rare cases of bullous eruptions such as erythema multiforme , Stevens - Johnson syndrome , toxic epidermal necrolysis , and Scleroderma - like changes usually preceded by peripheral lymphedema .", "label": "", "metadata": {}, "score": "70.591805"}
{"text": "The best overall response was the best response that was recorded from the start of treatment until disease progression .Duration of stable disease ( SD ) was measured from the start of treatment until the criteria for disease progression were met .", "label": "", "metadata": {}, "score": "70.66948"}
{"text": "Thyroid stimulating hormone ( TSH ) levels were evaluated in 224 patients ( 115 Cyramza plus FOLFIRI - treated patients and 109 placebo plus FOLFIRI - treated patients ) with normal baseline TSH levels .", "label": "", "metadata": {}, "score": "70.77222"}
{"text": "Median response duration in the 6 responders was 3.2 months .Median time to treatment failure was 2.0 months , with median survival of 4.2 months ( Figure 2 ) .", "label": "", "metadata": {}, "score": "70.81409"}
{"text": "These were reversible upon discontinuation of the infusion .Cases of cystoid macular edema ( CME ) have been reported in patients treated with Taxotere .", "label": "", "metadata": {}, "score": "71.13606"}
{"text": "If the vials are stored under refrigeration , allow the appropriate number of vials of Taxotere Injection Concentrate vials to stand at room temperature for approximately 5 minutes before use .", "label": "", "metadata": {}, "score": "71.36415"}
{"text": "vs. 8.7 mos .respectively .Median PFS for the D+PL group compared to the D+BV2 group was 8 mos .vs. 8.8 mos .respectively .", "label": "", "metadata": {}, "score": "71.47601"}
{"text": "[ 2 ] .Administration of docetaxel -- a product of Taxus baccata , the European yew -- at a dose of 75 mg / m\u00b2 has resulted in objective response rates of 52 % as first - line therapy in 31 evaluable patients with advanced breast cancer .", "label": "", "metadata": {}, "score": "71.48013"}
{"text": "2004 - 165 .OSHA Technical Manual , TED 1 - 0.15A , Section VI : Chapter 2 .Controlling Occupational Exposure to Hazardous Drugs .", "label": "", "metadata": {}, "score": "71.49242"}
{"text": "For response and toxicity rates , Wilson type 95 % confidence intervals ( CI ) were calculated .Response duration ( RD ) was measured from start of best response until relapse .", "label": "", "metadata": {}, "score": "71.69219"}
{"text": "OUTLINE : This is an open - label , randomized , multicenter study .Patients are randomized to 1 of 2 treatment arms .Arm I : Patients receive docetaxel IV over 1 hour on day 1 .", "label": "", "metadata": {}, "score": "71.71065"}
{"text": "Breast Cancer .For locally advanced or metastatic breast cancer after failure of prior chemotherapy , the recommended dose of Taxotere is 60 mg / m 2 to 100 mg / m 2 administered intravenously over 1 hour every 3 weeks .", "label": "", "metadata": {}, "score": "71.73523"}
{"text": "Eye Disorders .Cystoid macular edema ( CME ) has been reported in patients treated with Taxotere .Patients with impaired vision should undergo a prompt and comprehensive ophthalmologic examination .", "label": "", "metadata": {}, "score": "71.86624"}
{"text": "Pittsburgh , PA : Oncology Nursing Society .Obtain detailed allergy and concomitant drug information from the patient prior to Taxotere administration .Explain the significance of oral corticosteroids such as dexamethasone administration to the patient to help facilitate compliance .", "label": "", "metadata": {}, "score": "71.873085"}
{"text": "XTANDI can cause fetal harm when administered to a pregnant woman based on its mechanism of action .XTANDI is not indicated for use in women .", "label": "", "metadata": {}, "score": "71.961136"}
{"text": "Taxotere ( TAX - O - TEER ) ( docetaxel ) Injection Concentrate Intravenous Infusion .Read this Patient Information before you receive your first treatment with Taxotere and each time before you are treated .", "label": "", "metadata": {}, "score": "72.003525"}
{"text": "Patients were required to have at least one bidimensional measurable disease site , assessed by radiologic exam performed and documented within 28 days prior to registration .", "label": "", "metadata": {}, "score": "72.18628"}
{"text": "August 31 , 2012 for the treatment of metastatic castration - resistant prostate cancer for patients who have previously received docetaxel ( chemotherapy ) .A Marketing Authorization Application for XTANDI is currently under review by the .", "label": "", "metadata": {}, "score": "72.19356"}
{"text": "Co- administration of XTANDI with strong CYP2C8 inhibitors should be avoided if possible .If co - administration of XTANDI can not be avoided , reduce the dose of XTANDI .", "label": "", "metadata": {}, "score": "72.47035"}
{"text": "Taxotere is usually given every 3 weeks .Your doctor will decide how long you will receive treatment with Taxotere .Your doctor will check your blood cell counts and other blood tests during your treatment with Taxotere to check for side effects of Taxotere .", "label": "", "metadata": {}, "score": "72.482506"}
{"text": "Introduction .Patients with squamous cell carcinoma of head and neck ( SCCHN ) who had disease recurrence after primary surgery or chemoradiation therapy or who present with metastatic disease usually have a poor prognosis [ 1 ] .", "label": "", "metadata": {}, "score": "72.54904"}
{"text": "Future clinical trials in this setting should be based on the use of doublets , either platinum based or taxane based , with a targeted agent .", "label": "", "metadata": {}, "score": "72.603775"}
{"text": "94 % of the patients had good performance status ( 0 - 1 ) .Patients with prior chemo - radiotherapy were 97 % .The most common site of distant metastasis was lung , in 58 % of the patients .", "label": "", "metadata": {}, "score": "72.8196"}
{"text": "Cyramza Dosage and Administration .Recommended Dose and Schedule .Gastric Cancer .The recommended dose of Cyramza either as a single agent or in combination with weekly paclitaxel is 8 mg / kg every 2 weeks administered as an intravenous infusion over 60 minutes .", "label": "", "metadata": {}, "score": "72.97409"}
{"text": "Hormone Refractory Prostate Cancer .The safety and efficacy of Taxotere in combination with prednisone in patients with androgen independent ( hormone refractory ) metastatic prostate cancer were evaluated in a randomized multicenter active control trial .", "label": "", "metadata": {}, "score": "73.00185"}
{"text": "Six ( 21 % ) patients achieved PR , no patients achieved CR , and the overall response rate ( ORR ) was 21 % ( 95 % CI : 0.10 - 0.38 ; Table 3 ) .", "label": "", "metadata": {}, "score": "73.028"}
{"text": "The gemcitabine arm received more total cycles ( 875 ) than did the capecitabine arm ( 758 ) , Dr. Chan reported .The relative mean dose intensity was 73 % for the gemcitabine arm vs 60 % for the capecitabine arm .", "label": "", "metadata": {}, "score": "73.219734"}
{"text": "Tell your doctor if you have any side effect that bothers you or does not go away .These are not all the possible side effects of Taxotere .", "label": "", "metadata": {}, "score": "73.24925"}
{"text": "The chance of death in people who receive Taxotere is higher if you : . have liver problems .receive high doses of Taxotere . have non - small cell lung cancer and have been treated with chemotherapy medicines that contain platinum .", "label": "", "metadata": {}, "score": "73.26261"}
{"text": "Patients whose disease did not progress received RT according to institutional guidelines ( PF / RT ) .At the end of chemotherapy , with a minimal interval of 4 weeks and a maximal interval of 7 weeks , patients whose disease did not progress received radiotherapy ( RT ) according to institutional guidelines .", "label": "", "metadata": {}, "score": "73.38259"}
{"text": "Table 2 summarizes the results of the randomized clinical trials with gefitinib in first- and second - line therapy , in locally advanced disease and adjuvant setting and in special populations [ 24 , 25 , 29 - 38 ] .", "label": "", "metadata": {}, "score": "73.38394"}
{"text": "This leads to the production of microtubule bundles without normal function and to the stabilization of microtubules , which results in the inhibition of mitosis in cells .", "label": "", "metadata": {}, "score": "73.69774"}
{"text": "Infusion site reactions were generally mild and consisted of hyperpigmentation , inflammation , redness or dryness of the skin , phlebitis , extravasation , or swelling of the vein .", "label": "", "metadata": {}, "score": "73.89956"}
{"text": "The demographic characteristics were balanced between the two treatment arms .The median age was 55 years , 71 % were male , 71 % were Caucasian , 24 % were 65 years of age or older , 19 % had a prior curative surgery and 12 % had palliative surgery .", "label": "", "metadata": {}, "score": "73.967545"}
{"text": "Demographics and baseline characteristics were similar between treatment arms .Median age was 62 years ; 67 % of patients were men ; 82 % were White and 13 % were Asian ; 32 % had ECOG PS 0 ; 73 % had nonsquamous histology and 26 % had squamous histology .", "label": "", "metadata": {}, "score": "74.17404"}
{"text": "Life expectancy .Not specified .Hematopoietic .Absolute neutrophil count at least 1,500/mm^3 .Platelet count at least 100,000/mm^3 .Hemoglobin at least 8.0 g / dL .", "label": "", "metadata": {}, "score": "74.21402"}
{"text": "Changes in blood counts due to leukemia and other blood disorders may occur years after treatment with Taxotere .Skin Reactions including redness and swelling of your arms and legs with peeling of your skin .", "label": "", "metadata": {}, "score": "74.21644"}
{"text": "The earliest sign of infection may be fever .Follow your doctor 's instructions for how often to take your temperature while taking Taxotere .Call your doctor right away if you have a fever .", "label": "", "metadata": {}, "score": "74.333176"}
{"text": "No clinically significant ( i.e. , grade 3 or greater ) pericardial effusion .ECOG 0 - 2 ( 70 years of age and over ) OR .", "label": "", "metadata": {}, "score": "74.42583"}
{"text": "nausea and vomiting .diarrhea .mouth or lips sores . hair loss : in most cases normal hair growth should return .In some cases ( frequency not known ) permanent hair loss has been observed .", "label": "", "metadata": {}, "score": "74.45032"}
{"text": "Colorectal Cancer .The recommended dose of Cyramza is 8 mg / kg every 2 weeks administered by intravenous infusion over 60 minutes prior to FOLFIRI administration .", "label": "", "metadata": {}, "score": "74.457016"}
{"text": "[ 4 , 5 ] .Gefitinib has an inhibitory effect both on the autophosphorylation and downstream signaling , competing reversibly with the adenosine triphosphate ( ATP ) for the catalytic domain of EGFR .", "label": "", "metadata": {}, "score": "74.48338"}
{"text": "Respiratory : dyspnea , acute pulmonary edema , acute respiratory distress syndrome / pneumonitis , interstitial lung disease , interstitial pneumonia , respiratory failure , and pulmonary fibrosis have rarely been reported and may be associated with fatal outcome .", "label": "", "metadata": {}, "score": "74.60159"}
{"text": "Taxotere is a prescription anti - cancer medicine used to treat certain people with : . breast cancer .docetaxel , the active ingredient in Taxotere , or .", "label": "", "metadata": {}, "score": "74.65144"}
{"text": "Tell your doctor or nurse before your Taxotere treatment if you forget to take the corticosteroid dose or do not take it as your doctor tells you .", "label": "", "metadata": {}, "score": "74.803505"}
{"text": "Call your doctor for medical advice about side effects .You may report side effects to FDA at 1 - 800-FDA-1088 .General information about Taxotere .", "label": "", "metadata": {}, "score": "74.81495"}
{"text": "Demographics and baseline characteristics were similar between treatment arms .Median age was 62 years ; 67 % of patients were men ; 84 % were White and 12 % were Asian ; 33 % had ECOG PS 0 ; 74 % had non - squamous histology and 25 % had squamous histology .", "label": "", "metadata": {}, "score": "75.2222"}
{"text": "Patients must be never smoker , with a diagnosis of adenocarcinoma with the EGFR - positive mutations on exon 19 or 21 .Prophylactic cranial irradiation consists of 25 Gy cumulative dose over 10 fractions .", "label": "", "metadata": {}, "score": "75.37253"}
{"text": "About XTANDI \u00ae .XTANDI \u00ae ( enzalutamide ) capsules is an oral , once - daily androgen receptor inhibitor .XTANDI was approved by the .", "label": "", "metadata": {}, "score": "75.78418"}
{"text": "Median age was 62 years ; 57 % of patients were men ; 76 % were White and 20 % were Asian ; 48 % had ECOG PS 0 .", "label": "", "metadata": {}, "score": "75.802376"}
{"text": "Fluid Retention includes ( by COSTART ) : edema ( peripheral , localized , generalized , lymphedema , pulmonary edema , and edema otherwise not specified ) and effusion ( pleural , pericardial , and ascites ) ; no premedication given with the 60 mg / m 2 dose .", "label": "", "metadata": {}, "score": "76.13597"}
{"text": "The study was approved by the institutional protocol review board , the regional ethics committee , the Norwegian Medicines Agency and was carried out in accordance with the Declaration of Helsinki , International Conference on Harmony / Good Clinical practice and AstraZeneca 's policy on Bioethics .", "label": "", "metadata": {}, "score": "76.37778"}
{"text": "Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity .Quality of life is assessed at baseline , every 2 courses during study treatment , and then at study completion .", "label": "", "metadata": {}, "score": "76.421646"}
{"text": "Severe nail disorders were characterized by hypo- or hyperpigmentation , and occasionally by onycholysis ( in 0.8 % of patients with solid tumors ) and pain .", "label": "", "metadata": {}, "score": "76.77133"}
{"text": "Mechanism of Action .Ramucirumab is a vascular endothelial growth factor receptor 2 antagonist that specifically binds VEGF Receptor 2 and blocks binding of VEGFR ligands , VEGF - A , VEGF - C , and VEGF - D. As a result , ramucirumab inhibits ligand - stimulated activation of VEGF Receptor 2 , thereby inhibiting ligand - induced proliferation , and migration of human endothelial cells .", "label": "", "metadata": {}, "score": "77.07475"}
{"text": "Use only a 21 gauge needle to withdraw Taxotere from the vial because larger bore needles ( e.g. , 18 and 19 gauge ) may result in stopper coring and rubber particulates .", "label": "", "metadata": {}, "score": "77.28016"}
{"text": "Increased response rates were also seen in both BV groups compared to the control arm .Response rate ( RR ) ( defined as % of CR+PR ) was 44 % for arm 1 , 55 % for arm 2 , and 63 % for arm 3 .", "label": "", "metadata": {}, "score": "77.36534"}
{"text": "Acknowledgments .This study was sponsored by a grant from Eli Lilly and Sanofi - Aventis pharmaceuticals .Also , it was partially supported by the NIH Karmanos Cancer Institute core grant CA-22453 .", "label": "", "metadata": {}, "score": "77.453186"}
{"text": "Stability .Taxotere final dilution for infusion , if stored between 2 \u00b0 C and 25 \u00b0 C ( 36 \u00b0 F and 77 \u00b0 F ) is stable for 6 hours .", "label": "", "metadata": {}, "score": "77.4747"}
{"text": "Ask your doctor or pharmacist if you are not sure . are pregnant or plan to become pregnant .Taxotere can harm your unborn baby . are breastfeeding or plan to breastfeed .", "label": "", "metadata": {}, "score": "77.48028"}
{"text": "Instruct patients to monitor their temperature frequently and immediately report any occurrence of fever .Instruct patients to report myalgia , cutaneous , or neurologic reactions .", "label": "", "metadata": {}, "score": "77.50809"}
{"text": "Lactation .There is no information on the presence of ramucirumab in human milk , the effects on the breast - fed infant , or the effects on milk production .", "label": "", "metadata": {}, "score": "77.831436"}
{"text": "DO NOT FREEZE OR SHAKE the infusion solution .DO NOT dilute with other solutions or co - infuse with other electrolytes or medications .Store diluted infusion for no more than 24 hours at 2 \u00b0 C to 8 \u00b0 C ( 36 \u00b0 F to 46 \u00b0 F ) or 4 hours at room temperature ( below 25 \u00b0 C [ 77 \u00b0 F ] ) .", "label": "", "metadata": {}, "score": "77.8438"}
{"text": "23 , pp .5323 - 5333 , 2005 .View at Google Scholar .6 , no .12 , pp .4885 - 4892 , 2000 .", "label": "", "metadata": {}, "score": "77.9601"}
{"text": "23 , no .11 , pp .2513 - 2520 , 2005 .View at Publisher \u00b7 View at Google Scholar .LBA13 ) .", "label": "", "metadata": {}, "score": "78.02504"}
{"text": "Infertility : Advise females of reproductive potential regarding potential infertility effects of Cyramza [ see Use in Specific Populations ( 8.3 ) ] .Revised : April 2015 .", "label": "", "metadata": {}, "score": "78.077614"}
{"text": "Severe hand and foot syndrome has been reported .Cases of permanent alopecia have been reported .Gastrointestinal : abdominal pain , anorexia , constipation , duodenal ulcer , esophagitis , gastrointestinal hemorrhage , gastrointestinal perforation , ischemic colitis , colitis , intestinal obstruction , ileus , neutropenic enterocolitis and dehydration as a consequence to gastrointestinal events have been reported .", "label": "", "metadata": {}, "score": "78.29716"}
{"text": "Renal .Not specified .Other .Not pregnant or nursing .Negative pregnancy test .Fertile patients must use effective contraception during and for 6 months after study participation .", "label": "", "metadata": {}, "score": "78.31984"}
{"text": "Gefitinib is an oral , reversible , tyrosine kinase inhibitor of epidermal growth factor receptor ( EGFR ) that plays a key role in the biology of non small cell lung cancer ( NSCLC ) .", "label": "", "metadata": {}, "score": "78.351845"}
{"text": "Distribution : The initial rapid decline represents distribution to the peripheral compartments and the late ( terminal ) phase is due , in part , to a relatively slow efflux of docetaxel from the peripheral compartment .", "label": "", "metadata": {}, "score": "78.36466"}
{"text": "Your doctor should do routine blood tests during treatment with Taxotere .This will include regular checks of your white blood cell counts .If your white blood cells are too low , your doctor may not treat you with Taxotere until you have enough white blood cells .", "label": "", "metadata": {}, "score": "78.393036"}
{"text": "Acute Myeloid Leukemia ( AML ) , a type of blood cancer , can happen in people who take Taxotere along with certain other medicines .", "label": "", "metadata": {}, "score": "78.569374"}
{"text": "Tumor response was assessed radiographically with standard methods using RECIST criteria [ 21 ] every 4 cycles ( approximately 2 months ) .Toxicity was evaluated before each cycle .", "label": "", "metadata": {}, "score": "78.6653"}
{"text": "Due to the small number of responders ( . , the 80 % confidence level was used for the CI of RD .Time to treatment failure ( TTF ) was measured from registration until early discontinuation of treatment , first observation of progressive disease , or death from any cause , whichever occurred first .", "label": "", "metadata": {}, "score": "78.68074"}
{"text": "Medivation .Medivation , Inc. is a biopharmaceutical company focused on the rapid development of novel therapies to treat serious diseases for which there are limited treatment options .", "label": "", "metadata": {}, "score": "78.741104"}
{"text": "Taxotere infusion solution is supersaturated , therefore may crystallize over time .If crystals appear , the solution must no longer be used and shall be discarded .", "label": "", "metadata": {}, "score": "79.3365"}
{"text": "Vision Problems including blurred vision or loss of vision .Taxotere Injection contains alcohol .The alcohol content in Taxotere Injection may impair your ability to drive or use machinery right after receiving Taxotere Injection .", "label": "", "metadata": {}, "score": "79.3701"}
{"text": "feeling short of breath .constipation . decreased appetite . changes in your fingernails or toenails . swelling of your hands , face or feet .", "label": "", "metadata": {}, "score": "79.82699"}
{"text": "It is unclear why these data differ so greatly , but some have proposed that it may due to the time intervals at which paclitaxel and docetaxel are given .", "label": "", "metadata": {}, "score": "79.84287"}
{"text": "205 - 216 , 2000 .View at Google Scholar \u00b7 View at Scopus . E. Lee and J. W. Wang , Statistical Methods for Survival Data Analysis , John Wiley & Sons , New York , NY , USA , 3rd edition , 2003 .", "label": "", "metadata": {}, "score": "80.06375"}
{"text": "Docetaxel is an antineoplastic agent belonging to the taxoid family .It is prepared by semisynthesis beginning with a precursor extracted from the renewable needle biomass of yew plants .", "label": "", "metadata": {}, "score": "80.09088"}
{"text": "Keep the vial in the outer carton in order to protect from light .Calculate the dose and the required volume of Cyramza needed to prepare the infusion solution .", "label": "", "metadata": {}, "score": "80.0981"}
{"text": "Patients with more severe side effects or persistent toxicity despite dose reductions were withdrawn from the study .Patients suspected to have interstitial lung disease ( ILD ) were immediately taken off the study medication .", "label": "", "metadata": {}, "score": "80.2079"}
{"text": "Cyramza is formulated in glycine ( 9.98 mg / mL ) , histidine ( 0.65 mg / mL ) , histidine monohydrochloride ( 1.22 mg / mL ) , polysorbate 80 ( 0.1 mg / mL ) , sodium chloride ( 4.383 mg / mL ) , and Water for Injection , USP , pH 6.0 .", "label": "", "metadata": {}, "score": "80.29336"}
{"text": "The median response duration ( RD ) for the 6 PR patients was 3.2 months ( 80 % CI : 2.0 - 6.1 months ) .", "label": "", "metadata": {}, "score": "80.40266"}
{"text": "XTANDI ( enzalutamide ) is an androgen receptor inhibitor that acts on different steps in the androgen receptor signaling pathway .XTANDI has been shown to competitively inhibit androgen binding to androgen receptors , inhibit androgen receptor nuclear translocation and interaction with DNA .", "label": "", "metadata": {}, "score": "80.53172"}
{"text": "April 2005 .Primary Completion Date .April 2005 ( final data collection date for primary outcome measure ) .Eligibility Criteria ICMJE .DISEASE CHARACTERISTICS : .", "label": "", "metadata": {}, "score": "80.76126"}
{"text": "Renal : renal insufficiency and renal failure have been reported , the majority of these cases were associated with concomitant nephrotoxic drugs .Metabolism and nutrition disorders : cases of hyponatremia have been reported .", "label": "", "metadata": {}, "score": "80.82535"}
{"text": "Treatment cycles on both arms were repeated every 2 weeks .Patients who discontinued one or more components of treatment because of an adverse event were permitted to continue therapy with the other treatment component(s ) until disease progression or unacceptable toxicity .", "label": "", "metadata": {}, "score": "80.8595"}
{"text": "Gefitinib ( ZD1839 , Iressa ) is an orally administered , reversible tyrosine kinase inhibitor ( TKIs ) of epidermal growth factor receptor ( EGFR ) , belonging to the smallmolecule class ( quinazoline - derivative molecule ) [ 1 ] .", "label": "", "metadata": {}, "score": "81.3179"}
{"text": "Time to progression ( TTP ) was measured from registration until the date of documented progressive disease .Patients still progression - free were censored as of the date of their last tumor assessment .", "label": "", "metadata": {}, "score": "82.138535"}
{"text": "Please refer to [ see How Supplied/ Storage and Handling ( 16.3 ) ] .If Taxotere Injection Concentrate , initial diluted solution , or final dilution for infusion should come into contact with the skin , immediately and thoroughly wash with soap and water .", "label": "", "metadata": {}, "score": "82.16949"}
{"text": "Withdraw the required volume of Cyramza and further dilute with only 0.9 % Sodium Chloride Injection in an intravenous infusion container to a final volume of 250 mL. Do not use dextrose containing solutions .", "label": "", "metadata": {}, "score": "82.214386"}
{"text": "Arm II : Patients receive docetaxel IV over 30 minutes on days 1 , 8 , and 15 .Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity .", "label": "", "metadata": {}, "score": "82.38211"}
{"text": "Withhold Cyramza for urine protein levels that are 2 or more grams over 24 hours .Reinitiate Cyramza at a reduced dose once the urine protein level returns to less than 2 grams over 24 hours .", "label": "", "metadata": {}, "score": "82.422325"}
{"text": "12 , pp .2237 - 2246 , 2003 .View at Publisher \u00b7 View at Google Scholar .290 , no .16 , pp .", "label": "", "metadata": {}, "score": "83.20159"}
{"text": "Orlando , Florida .Title : Enzalutamide monotherapy : Phase 2 study results in hormone - na\u00efve prostate cancer patients ( Abstract # 18 ) .", "label": "", "metadata": {}, "score": "83.72507"}
{"text": "Withhold Cyramza prior to surgery .Resume following the surgical intervention based on clinical judgment of adequate wound healing .If a patient develops wound healing complications during therapy , discontinue Cyramza until the wound is fully healed [ see Dosage and Administration ( 2.3 ) ] .", "label": "", "metadata": {}, "score": "83.96743"}
{"text": "Contact of the Taxotere concentrate with plasticized PVC equipment or devices used to prepare solutions for infusion is not recommended .One - vial Taxotere ( Injection Concentrate ) .", "label": "", "metadata": {}, "score": "83.98593"}
{"text": "17 , no .5 , pp .1413 - 1424 , 1999 .View at Google Scholar .35 , no . 8 , pp .", "label": "", "metadata": {}, "score": "84.16554"}
{"text": "Use of a protein sparing 0.22 micron filter is recommended .Flush the line with sterile sodium chloride ( 0.9 % ) solution for injection at the end of the infusion .", "label": "", "metadata": {}, "score": "84.244095"}
{"text": "Gastric Adenocarcinoma .Treatment is repeated every three weeks .Patients must receive premedication with antiemetics and appropriate hydration for cisplatin administration [ see Dosage and Administration ( 2.7 ) ] .", "label": "", "metadata": {}, "score": "84.419"}
{"text": "Cyramza Description .Cyramza ( ramucirumab ) is a recombinant human IgG1 monoclonal antibody that specifically binds to vascular endothelial growth factor receptor 2 .Cyramza has an approximate molecular weight of 147 kDa .", "label": "", "metadata": {}, "score": "84.46608"}
{"text": "Primary endpoint is progression - free survival ; secondary endpoints are overall survival , tumor response rate , disease control rate , time to progression , duration of response , and time to worsening of health - related quality of life .", "label": "", "metadata": {}, "score": "84.71328"}
{"text": "Very rarely these cases resulted in a fatal outcome in patients who received premedication .Hepatic : rare cases of hepatitis , sometimes fatal primarily in patients with pre - existing liver disorders , have been reported .", "label": "", "metadata": {}, "score": "84.8081"}
{"text": "When fluid retention occurs , peripheral edema usually starts in the lower extremities and may become generalized with a median weight gain of 2 kg .", "label": "", "metadata": {}, "score": "85.16644"}
{"text": "View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .LBA2 ) . A. Morabito , M. Di Maio , E. De Maio , N. Normanno , and F. Perrone , \" Methodology of clinical trials with new molecular - targeted agents : where do we stand ? \"", "label": "", "metadata": {}, "score": "85.41947"}
{"text": "Materials and Methods .This is a double - blind , placebo controlled phase III study .Patients were randomized to one of 3 arms : .", "label": "", "metadata": {}, "score": "85.84271"}
{"text": "The primary endpoint of the study was objective tumor response ( complete response ( CR ) or partial response ( PR ) ) according to RECIST criteria in the two treatment groups .", "label": "", "metadata": {}, "score": "85.86553"}
{"text": "Thoroughly mix the infusion by gentle manual rotation .As with all parenteral products , Taxotere should be inspected visually for particulate matter or discoloration prior to administration whenever the solution and container permit .", "label": "", "metadata": {}, "score": "85.903175"}
{"text": "31 , pp .5034 - 5042 , 2006 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .17 , no .", "label": "", "metadata": {}, "score": "85.98488"}
{"text": "Each of these proteins has an extracellular ligand - binding domain , a single hydrophobic transmembrane domain and a cytoplasmic tyrosine kinase - containing domain .", "label": "", "metadata": {}, "score": "86.02757"}
{"text": "Serious allergic reactions are medical emergencies that can lead to death and must be treated right away .Tell your doctor right away if you have any of these signs of a serious allergic reaction : . trouble breathing . sudden swelling of your face , lips , tongue , throat , or trouble swallowing .", "label": "", "metadata": {}, "score": "86.242035"}
{"text": "Preparation and Administration .DO NOT use the two - vial formulation ( Injection Concentrate and diluent ) with the one - vial formulation .One - vial Taxotere ( Injection Concentrate ) .", "label": "", "metadata": {}, "score": "86.65497"}
{"text": "Reversible cutaneous reactions characterized by a rash including localized eruptions , mainly on the feet and/or hands , but also on the arms , face , or thorax , usually associated with pruritus , have been observed .", "label": "", "metadata": {}, "score": "86.78714"}
{"text": "Medivation Contacts : . Patrick Machado .Chief Business & Financial Officer .Anne Bowdidge .Senior Director , Investor Relations .Astellas Contacts : .", "label": "", "metadata": {}, "score": "86.935905"}
{"text": "3032 - 3037 , 2005 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .PRS.4 ) .11 , no . 2 , pp .", "label": "", "metadata": {}, "score": "87.46735"}
{"text": "The 6-month OS rate was 40 % ( 95 % CI : 24 - 56 % ) .The 12-month OS rate was 16 % ( 95 % CI : 3 - 28 % ) .", "label": "", "metadata": {}, "score": "88.560814"}
{"text": "This information does not take the place of talking with your doctor about your medical condition or your treatment .What is the most important information I should know about Taxotere ?", "label": "", "metadata": {}, "score": "88.881516"}
{"text": "25 , pp .5892 - 5899 , 2005 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .28 , no .", "label": "", "metadata": {}, "score": "89.01101"}
{"text": "Inspect vial contents for particulate matter and discoloration prior to dilution [ see Description ( 11 ) ] .Discard the vial , if particulate matter or discolorations are identified .", "label": "", "metadata": {}, "score": "89.4033"}
{"text": "Subscribe to receive email notifications whenever new articles are published .This material is provided for educational purposes only and is not intended for medical advice , diagnosis or treatment .", "label": "", "metadata": {}, "score": "89.78916"}
{"text": "15 , supplement , 2009 , ( abstract no .8011 ) .View at Google Scholar .28 , no .18 , supplement , 2010 , ( abstract no . LBA7005 ) .", "label": "", "metadata": {}, "score": "89.91611"}
{"text": "You and your doctor should decide if you will receive Taxotere or breastfeed .Tell your doctor about all the medicines you take , including prescription and over - the - counter medicines , vitamins , and herbal supplements .", "label": "", "metadata": {}, "score": "89.9694"}
{"text": "4 , pp .297 - 306 , 2001 .View at Google Scholar \u00b7 View at Scopus .20 , no . 9 , pp .", "label": "", "metadata": {}, "score": "90.47594"}
{"text": "Bilirubin normal .AST and ALT no greater than 2.5 times upper limit of normal ( ULN ) if alkaline phosphatase is no greater than ULN OR .", "label": "", "metadata": {}, "score": "90.653076"}
{"text": "Visually inspect the diluted solution for particulate matter and discoloration prior to administration .If particulate matter or discolorations are identified , discard the solution .", "label": "", "metadata": {}, "score": "90.6709"}
{"text": "Radiation was delivered with megavoltage equipment using once daily fractionation ( 2 Gy per day , 5 days per week for 7 weeks for a total dose of 70 - 72 Gy ) .", "label": "", "metadata": {}, "score": "90.911316"}
{"text": "15 , pp .2450 - 2456 , 2008 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .112 , no . 3 , pp .", "label": "", "metadata": {}, "score": "91.65689"}
{"text": "753 - 760 , 2010 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .366 , no .9496 , pp .", "label": "", "metadata": {}, "score": "91.73877"}
{"text": "Ophthalmologic : conjunctivitis , lacrimation or lacrimation with or without conjunctivitis .Excessive tearing which may be attributable to lacrimal duct obstruction has been reported .", "label": "", "metadata": {}, "score": "92.29649"}
{"text": "6 , pp .1593 - 1599 , 2002 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .10 , no . 1 , pp .", "label": "", "metadata": {}, "score": "92.381805"}
{"text": "20 , no .18 , pp .3815 - 3825 , 2002 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .", "label": "", "metadata": {}, "score": "93.41035"}
{"text": "17 , supplement 7 , pp .vii128-vii131 , 2006 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .", "label": "", "metadata": {}, "score": "93.48367"}
{"text": "383 - 389 , 2007 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .98 , no .5 , pp . 907 - 914 , 2008 .", "label": "", "metadata": {}, "score": "93.538864"}
{"text": "5 , pp .2053 - 2063 , 2000 .View at Google Scholar \u00b7 View at Scopus .6 , no .12 , pp .", "label": "", "metadata": {}, "score": "93.9239"}
{"text": "Median change in PSA was -99.6 % ( range -100 % to -86.5 % ) .Serum testosterone increased by a mean of 114 % at week 25 compared with baseline .", "label": "", "metadata": {}, "score": "94.700264"}
{"text": "Cyramza is a sterile , preservative - free , clear to slightly opalescent and colorless to slightly yellow solution for intravenous infusion following dilution and preparation .", "label": "", "metadata": {}, "score": "94.7803"}
{"text": "14 , no .6 , pp .922 - 930 , 2003 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .", "label": "", "metadata": {}, "score": "95.24972"}
{"text": "( See Figure 2 ) .There will be further analysis at the time survival data mature .Non - Small Cell Lung Cancer ( NSCLC ) .", "label": "", "metadata": {}, "score": "96.14112"}
{"text": "Terms & Privacy .Connect .Subscribe to receive email notifications whenever new articles are published .This material is provided for educational purposes only and is not intended for medical advice , diagnosis or treatment .", "label": "", "metadata": {}, "score": "96.57926"}
{"text": "No .Contacts ICMJE .Contact information is only displayed when the study is recruiting subjects .Listed Location Countries ICMJE .United States .Removed Location Countries .", "label": "", "metadata": {}, "score": "97.63219"}
{"text": "About Astellas Pharma Inc.Astellas Pharma Inc. is a pharmaceutical company dedicated to improving the health of people around the world through provision of innovative and reliable pharmaceuticals .", "label": "", "metadata": {}, "score": "99.25039"}
{"text": "Upon ligand binding , the ErbB receptors form either homo- or heterodimers and , following dimerization , auto- and transphosphorylation in tyrosine residues of the ErbB receptors occurs [ 3 ] .", "label": "", "metadata": {}, "score": "99.480896"}
{"text": "Know the medicines you take .Keep a list of them to show your doctor and pharmacist when you get a new medicine .How will I receive Taxotere ?", "label": "", "metadata": {}, "score": "101.88872"}
{"text": "View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .20 , no .21 , pp .4292 - 4302 , 2002 .", "label": "", "metadata": {}, "score": "108.74176"}
{"text": "To view content sources and attributions , please refer to our editorial policy .", "label": "", "metadata": {}, "score": "110.471725"}
{"text": "Received 1 January 2012 ; Accepted 22 January 2012 .Academic Editors : M. Emoto and M. Santarosa .Copyright \u00a9 2012 Zyad Kafri et al .", "label": "", "metadata": {}, "score": "110.726"}
{"text": "Academic Editors : A. M. Garcia - Lora and C. Nicco .Copyright \u00a9 2012 Olav Engebraaten et al .This is an open access article distributed under the Creative Commons Attribution License , which permits unrestricted use , distribution , and reproduction in any medium , provided the original work is properly cited .", "label": "", "metadata": {}, "score": "117.18245"}
{"text": "Corporate Communications .Mike Beyer .Sam Brown , Inc ( media for both companies ) .Received 17 December 2010 ; Accepted 15 March 2011 .", "label": "", "metadata": {}, "score": "122.15817"}
{"text": "Copyright \u00a9 2011Raffaele Costanzo et al .This is an open access article distributed under the Creative Commons Attribution License , which permits unrestricted use , distribution , and reproduction in any medium , provided the original work is properly cited .", "label": "", "metadata": {}, "score": "124.20076"}
{"text": "1891 Copyright \u00a9 2014 , 2015 , Eli Lilly and Company .All rights reserved .CYR-0003-USPI-20150424 .About .Terms & Privacy .", "label": "", "metadata": {}, "score": "137.79935"}
